

**Beyond One Million Genomes** 

# D5.1

# B1MG maturity level model and country-specific alignment within the model

Project Title (grant agreement No)	Beyond One Million Genomes (B1MG) Grant Agreement 951724					
Project Acronym	B1MG					
WP No & Title	WP5 - Delivering Personalise Implementation in Healthca					
WP Leaders	Astrid Vicente (INSA), Seren	a Scollen (ELIXIR Hub	)			
Deliverable Lead Beneficiary	12 - INSA					
Deliverable	D5.1 - B1MG maturity level within the model	model and country-s	specific alignment			
Contractual delivery date	31/05/2022	Actual delivery date	27/05/2022			
Delayed	No					
Authors	Alexandra Costa, Maria Luís Cardoso, Melissa Konopko, Xènia Pérez Sitja, Maria de Fátima Lopes, Arshiya Merchant, Osvaldo Santos, Mafalda Bourbon, Ilse Custers, Serena Scollen, Astrid Vicente					
Contributors	Adrian Thorogood and Regina Becker for WG2, Jeroen Belien for WG3, Ivo Gut for WG4, Tommi Nyronen for WG5, Ilse Custers for WP6					
Acknowledgements (not grant participants)	The Delphi panel of experts: Angel Carracedo, Anna Wedell, Anne Cambon-Thomsen, Annika Veimer, Bettina Lundgren, Eric Solary, Ewan Birney, Henrique Martins, Janis Klovins, Janna Saarela, Kathryn North, Mark Kroese, Mark Caulfield and Tapani Piha					
Deliverable type	Report					



Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



|--|

#### **Document History**

Date	Mvm	Who	Description
18/05/2022	0v1	Astrid Vicente (INSA)	Initial draft circulated to WP participants for feedback
19/5/2022	0v2	Astrid Vicente (INSA); Nikki Coutts (ELIXIR Hub)	WP comments addressed. Version circulated to B1MG-OG, B1MG-GB and Stakeholders for feedback
27/5/2022	1v0	Astrid Vicente (INSA)	Comments addressed.
27/05/2022	1v0	Nikki Coutts (ELIXIR Hub)	Version uploaded to the EC Portal

#### **Table of Contents**

1. Executive Summary	4
2. Contribution towards project objectives	5
Objective 1	5
Objective 2	5
Objective 3	6
3. Methods	6
4. Description of work accomplished	7
4.1 Design of the B1MG MLM: Literature Review and expert input from 1+MG/B1MG	7
4.2 Validation of the B1MG MLM content	8
4.3 Using the B1MG MLM – development of the process and a Tool Kit	10
4.4 Problems and solutions	10
5. Results	11
5.1 The B1MG MLM	11
5.2 Expert Delphi panel	12
5.3 Delphi exercise for validation of the B1MG MLM framework	15
5.4 The B1MG MLM Tool Kit and assessment procedure	16
6. Discussion	18
7. Conclusions	19





B1MG — D5.1 B1MG maturity level model and country-specific alignment within the model	3
8. Next steps	19
9. Impact	19
10. Annex 1	20
Table 10: Delphi Panel Round 2 General Comments	124





## **1. Executive Summary**

The Beyond One Million Genomes Maturity Level Model (B1MG MLM) was created as a tool for countries to self-assess the maturity level of implementation of genomics into their healthcare systems, according to a common matrix, and to define a path to optimization. As such, it aims to promote and facilitate the adoption of genomics in healthcare systems, close the best practice gaps across Europe, and make personalised medicine accessible to citizens and patients across Europe.

This report describes the design of the B1MG MLM and the content validation through a Delphi exercise. A draft version of the MLM was initially developed after careful review of recently published literature and input from experts from the <u>1+ Million Genomes Initiative</u><sup>1</sup> (1+MG) and the <u>Beyond 1 Million Genomes Project</u><sup>2</sup> (B1MG). This initial framework included 8 domains, each comprising several subdomains for which indicators and respective levels of maturity were assigned. The maturity level per indicator was rated in a scale from 1 to 5, namely from a non-existent or *Ad hoc* level of implementation to a level of maturity characterised by a system adaptable to opportunity and change, and in support of international cooperation.

The content and structure of the designed framework was validated through a two round Delphi exercise to find consensus among a panel of 14 high level experts. The process validated the 8 proposed domains, namely:

- I. Governance and strategy
- II. Investment and economic mode
- III. Ethics, legislation and policy
- IV. Public awareness and acceptance
- V. Workforce skills and organisation
- VI. Clinical organisation, infrastructure and tools
- VII. Clinical genomics guidelines and infrastructure
- VIII. Data management, standards and infrastructure.

The 147 items initially proposed were validated after inclusion of comments and suggestions by the Delphi expert panel. The final version of the B1MG MLM can be found <u>here</u><sup>3</sup>.

To facilitate the use of the B1MG MLM an Assessment Tool Kit was developed, including a User's Guide and an Assessment Tool. A pilot with voluntary countries is currently ongoing, to assess feasibility in real life healthcare settings, stimulate discussion among stakeholders across European health systems, address transferability of best practices, and finally discuss the development of an action plan for progress towards optimization.

<sup>&</sup>lt;sup>1</sup><u>https://digital-strategy.ec.europa.eu/en/policies/1-million-genomes</u> <sup>2</sup><u>https://b1mg-project.eu/</u> <sup>3</sup>https://b1mg-project.eu/resources/maturity-level-model





# 2. Contribution towards project objectives

With this deliverable, the project has reached or the deliverable has contributed to the following objectives/key results:

[Select 'Yes' (at least one) if the deliverable contributed to the key result, otherwise select 'No'.]

	Key Result No and description	Contributed				
<b>Objective 1</b> Engage local,	<ol> <li>B1MG assembles key local, national, European and global actors in the field of Personalised Medicine within a B1MG Stakeholder Coordination Group (WP1) by M6.</li> </ol>	No				
regional, national and European stakeholders to define the requirements for	<b>2.</b> B1MG drives broad engagement around European access to personalised medicine data via the B1MG Stakeholder Coordination Portal (WP1) following the B1MG Communication Strategy (WP6) by M12.	No				
cross-border access to genomics and personalised medicine data	<b>3.</b> B1MG establishes awareness and dialogue with a broad set of societal actors via a continuously monitored and refined communications strategy (WP1, WP6) by M12, M18, M24 & M30.	No				
	<b>4.</b> The open B1MG Summit (M18) engages and ensures that the views of all relevant stakeholders are captured in B1MG requirements and guidelines (WP1, WP6).	No				
<b>Objective 2</b>	Legal & Ethical Key Results					
Translate requirements for	<ol> <li>Establish relevant best practice in ethics of cross-border access to genome and phenotypic data (WP2) by M36</li> </ol>	No				
data quality, standards, technical infrastructure, and	<ol> <li>Analysis of legal framework and development of common minimum standard (WP2) by M36.</li> </ol>	No				
ELSI into technical specifications and implementation	<b>3.</b> Cross-border Data Access and Use Governance Toolkit Framework (WP2) by M36.	No				
guidelines that captures European	Technical Key Results					
best practice	<b>4.</b> Quality metrics for sequencing (WP3) by M12.	No				
	<b>5.</b> Best practices for Next Generation Sequencing (WP3) by M24.	No				
	<b>6.</b> Phenotypic and clinical metadata framework (WP3) by M12, M24 & M36.	No				
	<b>7.</b> Best practices in sharing and linking phenotypic and genetic data (WP3) by M12 & M24.	No				
	<b>8.</b> Data analysis challenge (WP3) by M36.	No				
	Infrastructure Key Results					
	<b>9.</b> Secure cross-border data access roadmap (WP4) by M12 & M36.	No				
	<b>10.</b> Secure cross-border data access demonstrator (WP4) by M24.	No				



<b>Objective 3</b>	<b>1.</b> The B1MG maturity level model ( WP5) by M24.	Yes
Drive adoption and support long-term operation by organisations at local, regional, national and European level by providing guidance on phased development (via the B1MG maturity level model), and a methodology for economic evaluation	<ol> <li>Roadmap and guidance tools for countries for effective implementation of Personalised Medicine (WP5) by M36.</li> </ol>	Yes
	<ol> <li>Economic evaluation models for Personalised Medicine and case studies (WP5) by M30.</li> </ol>	No
	<ol> <li>Guidance principles for national mirror groups and cross-border Personalised Medicine governance (WP6) by M30.</li> </ol>	No
	<ol> <li>Long-term sustainability design and funding routes for cross-border Personalised Medicine delivery (WP6) by M34.</li> </ol>	No

## 3. Methods

Implementing genomic medicine in healthcare settings can bring us one step closer to making personalised medicine a reality. Accurate, timely diagnostics, personalised treatment protocols and preventative approaches based on genomic information have a major impact on patients and their families and can improve efficiency in health systems. For instance, genomic data analysis may provide better and faster diagnosis for many conditions and determine a more effective treatment based on a patient's pharmacogenomics profile, while accurate genomic profiling of individuals is enabling a shift of medical practice towards disease prevention.

However, it is clear that European countries are currently at varying stages of maturity for implementing genomics in healthcare. To close the maturity gaps across Europe (and globally) and to promote the more effective usage of genomic information for clinical practice, countries need to be able to understand their needs and challenges, and plan their path towards optimised implementation. Recognizing this need prompted the B1MG WP5 to develop a support tool for countries to self-assess their maturity, according to a common matrix that addresses the crucial issues for implementation of genomics in healthcare. The B1MG Maturity Level Model (B1MG MLM) was created to meet this challenge, promoting strategic planning for genomics in healthcare, as well as the dialogue and cooperation among countries.

To this end, the following activities and methodologies were carried out:

- Designing the B1MG MLM (Figure 1): based on a literature review, WP5 brainstorming, critical advice and input from B1MG WPs and 1+MG Initiative WGs experts knowledgeable in different fields, we developed a first version of the MLM framework (see Section 4.1).
- Validation of the B1MG MLM (Figure 1): to validate the content of the first B1MG MLM version, a group of international senior experts in the field of genomics medicine, healthcare systems, public policy and data standards and infrastructure was invited to participate in a Delphi exercise (see Section 4.2).





• Developing a Tool Kit for application of the B1MG MLM: to support the process of applying the B1MG MLM in real world settings, we developed a Tool Kit including the MLM in a suitable online visualisation platform with Glossary, an Assessment Tool and a User's Guide. This Tool Kit is being tested in a pilot assessment by a group of volunteer pilot countries (see Section 4.3).




Figure 1. Overall development and validation of the B1MG MLM.

# 4. Description of work accomplished

# 4.1 Design of the B1MG MLM: Literature Review and expert input from 1+MG/B1MG





"domains"; "maturity model" AND "dimension"; "maturity model" AND "data"; "maturity model" AND "survey"; "maturity model" AND "indicators"; "maturity model" AND "process"; "maturity model" AND "Delphi"; "maturity level" AND "healthcare"; "implementation" AND "genomic data" AND "healthcare systems". Titles and abstracts of the retrieved articles were analysed to identify the relevant ones. A search for studies reporting the use of Delphi on raising healthcare consensus was also done.

Based on this initial literature review, a first draft of the MLM framework was designed, which included 8 domains. At this stage, discussions with the 1+MG WGs/B1MG WPLs provided critical advice, particularly with WGs 2, 3, 4, 5, and 6, as they involve experts in different fields including ethics and legal issues, data infrastructure, data and genomic standards, public health and health economics. The initial draft maintained the 8 domains, but aspects were re-worked following WP5 brainstorming to include the WGs suggestions and advice. The domain on ethical and legal issues was entirely developed by WG2, while the domain addressing health economic models had crucial input from WG6 members.

#### 4.2 Validation of the B1MG MLM content

To validate the initial draft proposal for the MLM framework, a group of experts was invited to enter the Delphi iterative process of reaching consensus. A group of international experts in the field of healthcare systems, public policy, data and genomics was identified by the B1MG team of international networks. Delphi experts were selected according to the following preferential criteria: 1) having senior leadership experience of national, European or international genomic medicine or personalised medicine-related initiatives (could be digital health or similar), and/or 2) having a medical background with expertise in public health, healthcare policy, genomic medicine and/or healthcare management, and/or 3) having experience in health policy for genomic medicine or personalised medicine.

Twenty-one experts were selected and invited to participate. Among the 16 experts who accepted the invitation, 14 completed the two rounds of the Delphi survey. The Delphi panel experts were invited by email to provide input on every item of the MLM framework, using a dedicated online platform.

In the first Round, the survey was divided into 10 sections. The first section was dedicated to gathering informed consent and expert's demographic information. In the second section, experts were asked about the relevance of the eight domains proposed as main blocks of the MLM framework structure. Further to their opinion about the relevance of each domain, experts were also able to add, remove or rephrase items as well as provide comments. The remaining 8 sections were each one dedicated to a domain, in a total of 147 items. For each domain, experts were interrogated about the suggested subdomains, indicators and respective maturity levels. For each indicator there was always a set of 5 maturity levels associated. Experts were asked to score the adequacy of the subdomains and indicators proposed according to a 5-point Likert scale ('strongly agree', 'agree', 'neither agree nor disagree', 'disagree', 'strongly disagree'). For every 'disagree' or 'strongly disagree' response, a free-text response box was available for participants to elaborate or further explain. An option of 'unable to answer' was also included. Any 'unable to answer' response was considered as a missing value.





As depicted in Figure 1, the items that did not reach the agreement level used as the consensus criteria to validate an item were included in the Round 2 survey.

For item validation and inclusion in the final B1MG MLM, or reformulation and reevaluation in the Delphi Round 2, decision criteria were established as follows:

- Items with an agreement rate ≥86% (Strongly agree + Agree) were accepted in the final B1MG MLM. For reporting purposes these were labelled as "Validated";
- Some items with an agreement rate ≥ 86% (Strongly agree + Agree) were slightly changed to accommodate very relevant comments from the expert panel, and accepted in the final B1MG MLM. For reporting purpose were labelled as "Validated with rewording";
- Items with an agreement rate <86% (Strongly agree + Agree) and cumulatively with a disagreement rate ≥7% (Disagree + Strongly Disagree), were reformulated according to comments from the expert panel for validation in Round 2. These items were labelled "Reformulated";
- Items with an agreement rate ≥79% (Strongly agree + Agree) and no disagreements (Disagree + Strongly Disagree), corresponding to a rate of Neither agree or disagree ≥21%, were accepted in the final B1MG MLM. For reporting purpose were labelled as "Validated";
- 5. Items with an agreement rate <86% (Strongly agree + Agree) without suggestions for improvement were deemed inconclusive and included for reevaluation in Round 2 with the original wording. For reporting purposes were labelled "Reevaluate".

For Round 2, each expert was asked to independently rank a total of 36 items ("Reformulated" and "Reevaluate"). Each expert also received a personalised report with his/her own scores in Round 1, as well as the group's collective response (percentage agreement/disagreement) to each statement, and the de-identified comments from all experts. This way, experts were given the chance to reconsider their responses in Round 2 in light of the group's responses in Round 1. For Round 2, there were only two answering possibilities: 'agree' and 'disagree'. For every 'disagree' response, a free-text response box was available to experts to elaborate or further explain. Items with an agreement rate ≥86% were validated and included in the final B1MG MLM.

Following Round 2, each expert received a personalised report by email with his/her own scores as well as the group's collective response (percentage agreement/disagreement) to each statement, and de-identified comments from all experts. For two domains, namely Domain II and Domain III, some experts still raised a few pertinent questions and concerns. After discussion with 1+MG/B1MG experts some minor changes were introduced. All experts received by email the final and validated through consensus MLM framework, and were asked to express and discuss any last opinions, concerns or doubts.

The Delphi survey was carried out using the Welphi® software. This online platform allowed the implementation of the survey, ensuring confidentiality and anonymity of experts throughout the Delphi exercise. Data were exported to Excel for further processing.





# 4.3 Using the B1MG MLM – development of the process and a Tool Kit

A process and a Tool Kit were developed to facilitate the process of applying the B1MG MLM in real world settings. The general process includes 5 stages, namely:

- 1. Identification of stakeholders and assembly of the Assessment Team: a multidisciplinary group of experts from the ministries of health and other relevant national or regional agencies
- 2. Self-assessment: the Assessment Team completes the Assessment Tool, including rationale and supporting evidence, for all or selected domains according to expertise
- 3. Consensus building and completion of the Assessment Tool Consensus Tab, documenting rationale and supporting evidence
- 4. Analysis of assessment outcomes: identification of weaknesses and requirements for optimization
- 5. Developing an action plan: definition of current and desired maturity status, and path towards optimization according to the common matrix underlying the MLM

To support this process, we developed a Tool Kit including the MLM in a suitable online visualisation platform with Glossary, an Assessment Tool and a User's Guide.

A pilot is currently ongoing testing the Tool Kit and the general assessment process in 10 European countries. The main goals are to assess feasibility, stimulate discussion among stakeholders across European health systems, address transferability of Best Practices and address development of an action plan for progress towards optimization. Volunteer countries across Europe are participating in this challenge.

### 4.4 Problems and solutions

Delphi expert selection was carried out according to a number of criteria to ensure that the groups of experts were highly experienced in genomic medicine, leaders of national or international initiatives in genomic or personalised medicine and had a good understanding of healthcare systems. As such, most experts were medical doctors, and all were leaders in their fields and experts in at least one of the domains covered by the MLM. This meant a limited pool of 21 high level experts would fit this criteria, and were invited to participate. Of this group, 16 accepted the invitation, and 14 carried out the full assessment. We did not fully achieve the desired balanced geographical coverage sought, and had more northern and central European representation than eastern and southern. While we could not mitigate the less balanced geographical representation, the seniority, wide experience and deep knowledge on genomic medicine of this pool of experts was extremely reassuring that the validation exercise would be





successful. We were also extremely pleased that all 14 experts who started completed the two rounds of the Delphi, which were challenging and very time consuming.

The Delphi exercise was slightly delayed due to three main factors:

- 1. We prioritised a high response rate from experts, and therefore extended deadlines to suit their schedules;
- 2. The Delphi exercise was carried out during summer, so had to accommodate summer vacation timings, which differ between European countries;
- 3. After the Delphi Round 2 all items were validated. However we still received a number of relevant comments and reached out again to WG experts for support on how to best accommodate these without changing the consensus.

These delays were compensated with a fast turnaround of analysis in between rounds and for the final version of the MLM.

## 5. Results

### 5.1 The B1MG MLM


The MLM framework is structured as a matrix of domains, subdomains and related indicators and maturity levels. The proposed 8 domains cover topics agreed as crucial for assessing the maturity stage of healthcare systems in implementing genomics in clinical practice, namely:

- I. Governance and strategy
- II. Investment and economic model
- III. Ethics, legislation and policy
- IV. Public awareness and acceptance
- V. Workforce skills and organisation
- VI. Clinical organisation, infrastructure and tools
- VII. Clinical genomics guidelines and infrastructure
- VIII. Data management, standards and infrastructure

The 8 domains comprise a total of 41 subdomains, 49 indicators and 49 sets of 5 maturity levels (one set for each indicator). The 5 maturity levels reflect a stepwise path towards higher genomic practice maturity, from *Ad hoc* practices to practices that are widely adopted, adaptable to new opportunities and novel developments and supportive of international cooperation (shown in Figure 2). Overall, the MLM is intended to provide a common matrix for countries to self-assess their current status and plan a staged progression towards optimization.







**Figure 2**. B1MG MLM maturity level framework - towards an increased maturity of genomics in healthcare systems.

### 5.2 Expert Delphi panel

The first version of the B1MG MLM was validated by a Delphi panel with senior experts, who completed both rounds of the Delphi exercise. Figure 3 provides a demographic and professional characterisation of the expert. Table 1 provides a characterization of the expert panel, while Figure 3 shows their geographical distribution. All experts originated from European countries except one, who provided an international perspective.





**Table 1:** Characterization of the expert panel by sex, type of organization, position within the organization and main expertise areas.

Character	istic	No. (%)	
Total		14 (100%)	
Sex			
Total		14 (100%)	
	Female	6 (43%)	
	Male	8 (57%)	
Type of or	rganisation <sup>*</sup>		
Total		13 (100%)	
	Ministry	1 (8%)	
	Public Health organisations	2 (16%)	
	Academia or Research centre	10 (77%)	
Position w	vithin the organisation*		
Total		10 (100%)	
	CEO	2 (20%)	
	Director	4 (40%)	
	Head of clinic/scientific council	2 (20%	
	Advisor/Consultant	2 (20%)	

Main Areas of expertise (more than 1)\*





Total		9 (100%)	
	Genetics/Genomics (clinical/research)	7 (78%)	
	Medicine	3 (33%)	
-	Public Policies/Administration	2 (22%)	
-	Public Health	2 (22%)	
Country	,		
Total		11 (100%)	




Figure 3. Geographical distribution of the Delphi expert panel.





# 5.3 Delphi exercise for validation of the B1MG MLM framework

The first version of the B1MG MLM framework submitted to Round 1 for validation through Delphi panel consensus included 8 domains. These covered topics crucial for assessing the maturity stage of healthcare systems in implementing genomics into regular care. For each domain, subdomains were identified, and the level of maturity associated to each subdomain was assessed by ascribing a maturity level, between 1 and 5, to appropriate indicators. The original wording for each item included in the first version of the MLM framework is shown in Annex 1 (Tables 1-8).

Overall, the validation of the B1MG MLM using the Delphi method took around four months (Figure 4). During the two rounds, priority was given to having a 100% response rate from the Delphi expert panel over meeting pre-established deadlines. Both rounds were closed only after all 14 experts responded to the Delphi survey.



Figure 4. Timeline of the Delphi validation of the B1MG MLM.

The Delphi Round 1 allowed the validation, through expert panel consensus, of 76% of the 147 items that constitute the initial MLM version (Table 2). All remaining items were validated in Round 2.

The rates of approval and rewording differed between the 8 domains (Table 1), with Domain II "Investment and economic model" requiring the most extensive rephrasing. Two domains, namely Domain V "Workforce skills and organisation" and Domain VII "Clinical genomics guidelines and infrastructure", were fully accepted and validated in Round 1. After round 2, two domains suffered a minor rearrangement (merging of subdomains), namely "Investment and economic model" and "Ethics, legislation and policy", following expert suggestions.

Annex 1, Tables 1 to 8 show the descriptive statistics per item (Domains and respective Subdomains, Indicators and Maturity Levels), including rating by percentage (%) of experts, level of decision per item, experts comments per item, and rewording proposal in the 2 rounds. Tables 9 and 10 compile all other general expert comments of Round 1 and Round 2, respectively. Overall, all initial 147 items, distributed by the initially proposed 8 domains, were validated in the two Delphi rounds and included in the final MLM framework, 76% in the initial wording, and 24% with rewording to include the suggestions made by the Delphi expert panel.





	Approved in	Rephrased	Included in	
and repirase			•	
and rephrase	d items in Round 1 an	d items included in Round 2		

Table 2. Quantitative analysis of Round 1 results, namely number and percentage of validated

Domains	items	Approved in Round 1	% Approved	Rephrased after Round 1	% Rephrased	Included in Round 2	% reevaluation
I	10	9	90	3	30	1	10
II	16	4	25	10	63	12	75
III	34	24	71	9	26	10	29
IV	10	5	50	3	30	5	50
v	18	18	100	0	0	0	0
VI	16	11	69	7	44	5	31
VII	19	19	100	0	0	0	0
VIII	24	21	88	2	8	3	13
Total	147	111	76	34	23	36	24

# 5.4 The B1MG MLM Tool Kit and assessment procedure

The Tool Kit includes:

- The full B1MG MLM framework in an online platform, namely GitHub. The online platform allows easy access to the model, with a simple but very clear visualisation of all domains, subdomains, indicators and maturity levels. The MLM includes a linked Glossary for clarification of definitions and concepts.
- The Assessment Tool is an excel file designed to:
  - Collect and record data, namely the:
    - Assessment Team members, with affiliation, contact, and Domains assessed according to expertise
    - The maturity level assessment per indicator by each Assessment Team member
    - Rationale and supporting evidence for maturity level choice for each indicator
  - Register the consensus for each Domain 1 per country or region
  - Register the rationale and supporting evidence for the consensus maturity level assessment per indicator
- An informative User's Guide describing the development of the B1MG MLM, the assessment process, the consensus building phase, the analysis phase and the development of an action plan for optimization.





The outcomes of the assessment process (Figure 4) provide the current status of maturity regarding practices in genomic medicine, systematically identifying areas of strengths and weaknesses according to a structured framework. This information can be used to set goals, define areas of priority investment and establish an action plan. The B1MG MLM process and tool can be:

- An instrument for self-assessment of current status, but also a framework for progression
- The indicators and maturity levels provide reference points to define the desired maturity status, and the processes, structures and capacities needed to reach higher maturity
- A support tool to be used considering other issues to define the maturity goals, eg healthcare system context, objectives and resources
- Once an action plan is implemented, the indicators can be used to monitor progress along the path for maturity
- The Assessment Team and other stakeholders with relevant expertise may be engaged to help implement the action plan.




Figure 4. Description of the general process for using the MLM.

The assessment procedure and Tool Kit are currently being piloted in volunteer countries. To gather these countries' impressions regarding the B1MG MLM usability and challenges, we developed a pilot survey. We expect the answers to this survey will help improve the self-assessment process and the Tool Kit.

The B1MG MLM was presented to several audiences, namely:



- Astrid Vicente for WP5, "B1MG Maturity Level Model", the Global Health Implementation Forum (GHIF), "End-to-End Standards Implementations Session", 24th September 2020;
- Astrid Vicente, The B1MG MLM an update. 1+MG Special Group meeting, October 19th, 2021
- Astrid Vicente for WP5, "Delivering Personalised Medicine cross-borders: Implementation in Healthcare systems and Societal Impact", the Stakeholder Meeting, 21st October 2020;
- Astrid Vicente for WP5, "B1MG Maturity Level Model", the Global Health Implementation Forum (GHIF), 17th November 2021;
- Astrid Vicente for WP5, "How ready are European healthcare systems regarding the use of genomics in medicine? The Beyond 1 Million Genomes (B1MG) Maturity Level Model ", Workshop "Integrating the use of genomic data in personalised healthcare: implications across the board" at the European Public Health (EPH) Conference, 11th November 2021;

A manuscript describing the design and content-validation of the B1MG MLM is in preparation.

### 6. Discussion

In the area of healthcare, maturity models are necessarily cross-disciplinary in nature, and this is clearly reflected in the B1MG MLM. The 8 domains covered in the model are essential for the implementation of genomics in healthcare routine: Governance and strategy, Investment and economic model, Ethics, legislation and policy, Public awareness and acceptance, Workforce skills and organisation, Clinical organisation, infrastructure and tools, Clinical genomics guidelines and infrastructure and Data management, standards and infrastructure.

Altogether, the results of the Delphi exercise, namely that there were no rejected domains in the initial proposal of the model; evidence that a good preparation and deep reflection and debate previous to the Delphi survey, including the extensive literature review; the WP5 team brainstorming and the 1+MG expert inputs; were essential to the success of the exercise.

Two domains, namely Domain V, regarding "Workforce skills and organisation", and Domain VII, regarding "Clinical genomics guidelines and infrastructure", were fully accepted and validated in Round 1. These results evidence the progress and consensus in these two areas, likely to be the most developed, or at least the most discussed, among European countries.

Among the eight domains of the B1MG\_MLM framework, Domain II, "Investment and economic model", had lower agreement rates from experts in the first round of the Delphi process and was the least consensual. After round 2, although consensus was reached, we still addressed some comments from the experts that we considered relevant. For this, we consulted again the 1+MG WG6 Health economics and outcomes research, and made minor rewording to accommodate these last comments. The area of economic evaluation of genomic medicine and economic impact evaluation is still underdeveloped, and major efforts need to be made to define appropriate models that consider not only cost-effectiveness but also the benefit for patients and their families, and citizens at large. Another domain that required more effort to reach consensus was Domain III, "Ethics, legislation and policy". Again, this reflects the controversies and intense discussions, at the national and international levels, on data access, security and privacy. Both these areas are crucial to ensure equity of access to all citizens.





# 7. Conclusions

The B1MG MLM is a unique tool enabling the identification of strengths and areas that need more attention and investment for the implementation of genomics in healthcare. The MLM has been developed and validated as a common matrix that will contribute to closing the maturity level gaps across Europe. A complementary procedure and Tool Kit to facilitate its use in healthcare systems maturity assessments was developed and is currently being tested in volunteer pilot countries.

The final goal of the overall effort is to develop stronger and more effective healthcare systems for personalised medicine globally. The overall vision is to benefit all citizens and patients with equity of access to personalised medicine.

### 8. Next steps

A manuscript describing the B1MG MLM design and content validation is in preparation for publication.

A pilot is now running in 10 volunteer countries (Belgium, Denmark, Finland, Italy, Lithuania, Luxembourg, Portugal, Slovenia, Spain and Germany) to test the MLM in real world settings. Results of this pilot, focusing on the process and the Tool Kit (not on the national maturity levels) will be presented and discussed in a workshop planned to take place at INSA (Lisbon) in October 2022. This workshop will provide recommendations for the use of the B1MG MLM and for the development of action plans. The outcomes will be widely disseminated, and the B1MG MLM and Tool Kit will be made freely available globally.

As evidenced by results presented in this report, the area of Health Economic models still needs more research and data to better understand the economic impact and develop solid models for health care. It is thus very relevant that WP5 organises a workshop on this topic, taking place in May in Lisbon, Portugal. The results from this workshop will provide recommendations for what steps need to be taken, including more research, to develop appropriate health economic models for genomics in healthcare.

# 9. Impact

The validated B1MG MLM framework generated great interest among the 1+MG country representatives, National Mirror Groups and Working Groups, as well as from genomics experts globally. This interest recognizes the need for a structured tool to assess the challenges of each country or region in the implementation of genomic medicine in health systems and to plan how these can be overcome towards optimization. The B1MG MLM provides this tool.







## 10. Annex 1

 Table 1: Descriptive results for Domain I and respective sub-sections

	Round 1					Round 2			
ltem	Rating by % of experts		Comments	Decision after	Rewording Proposal	Agree %	Comments	Decision after	
Domain I: Governance and Strategy	Not Relevant     Relevant       0%     100%		-	Round 1 Validated	-	-	-	Round 2 N/A	
ltem	Disagree	by % of e Neutra	Agreeme	Comments	Decision after Round 1	Rewording Proposal	Agree %	Comments	Decision after Round 2
Subdomain 1: Governance	0%	0%	nt 100%	-	Validated		-	-	N/A
Indicator 1: Country/region has a dedicated governance body for genomics in healthcare	14%	0%	86%	•1) We can see a solution that there are several or integrated governance bodies.; 2) The scale is very demanding as regards the rather strict definition.	Validated with rewording	Country/regi on has a dedicated governance for genomics in healthcare	-	-	N/A



Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



Suggestion:
""Country/regi
on has
dedicated
governance for
genomics in
healthcare".
Scale
1 - No
governance; 2
- Elements of
governance
exist but they
are not fully
functional; 3 -
Governance
for genomics
has bee
defined but
elements (e.g.
full legal
mandate) are
still missing. ;
4 - Governance
is fully
operating, led
centrally,
possibly in a
dedicated
agency or
body.; 5 - as
suggested.".
5455551CU
•I think there
is potential for
confusion
regarding the
term
governance-
governance.





, ,	
	currently the
	framework
	states with
	legal mandate
	to establish
	and enforce
	legal,
	professional
	conduct,
	conventions
	and practices
	related to
	genomic
	medicine. This
	is a very wide
	definition - in
	practice such
	organisations
	are likely not
	to have a legal
	mandate and
	effective
	governance
	can be
	provided
	through
	professional,
	financial and
	health system
	governance.
	Also any
	governance
	arrangements
	for genomic
	medicine will
	not be
	specifically for
	this area only
	but will form





				part of the governance arrangements for medicine. To suggest that genomic medicine requires a completely separate and different standard of legal governance from other areas of medicine would in my opinion not be appropriate.					
ltem		Rating by Not adequate	% of experts Adequate	Comments	Decision after	Rewording Proposal	Agree %	Comments	Decision after
MLs	<ol> <li>Genomics in healthcare is not Validated in national/reg ional health plans</li> <li>Inclusion of genomics in healthcare in relevant national/reg ional health</li> </ol>	29%	71%	<ul> <li>There could be a level stating "under development" or "under discussion".</li> <li>Move international cooperation to specific subdomains?.</li> <li>Please see my earlier</li> </ul>	Reformula ted	1 - No dedicated governance for genomics in healthcare 2 - Elements of governance exist but they are not fully functional 3 - Scope of governance	93%	I think there needs to be an explanation of what is meant by governance. It is not in the glossary. It has different meaning in different countries.	Round 2 Validated





plans is	comment on	 for genomics	Do you	
under	governance	has been	mean	
discussion	body- greater	defined but	healthcare	
3. Genomics	clarity	elements are	services,	
in	required.	still under	funders,	
healthcare	Otherwise	development	regulators,	
is Validated	maturity levels	4 - There is a	political,	
in relevant	are fine.	governance	health	
national/reg		body that is	professional	
ional health		fully	groups or	
plans		operating,	all or any of	
4. Genomics		led centrally,	these. All 5	
in		and activities	points can	
healthcare		are	relate to	
is		monitored	one or more	
implemente		based on a	of these	
d as part of		work plan.	different	
national/reg		5-	types of	
ional health		Governance	governance	
and other		body is	arrangemen	
relevant		institutionali	ts.	
plans (e.g.		sed,		
education or		recognized		
research)		as the lead		
5. Genomics		for genomics		
in		in		
healthcare		healthcare,		
is		and is open		
implemente		to novel		
d in health		development		
and other		s and		
relevant		supportive of		
plans, and is		international		
periodically		cooperation.		
evaluated				
for				
optimization				
, taking into				
account				



#### Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



	novel developmen ts at the internationa l level.									
ltem		Rating Disagree ment	by % of e Neutra l	Agreeme nt	Comments	Current Decision	Rewording proposal	Agree %	Comments	Decision after Round 2
Subdo Priori	omain 2: ity	0%	7%	93%	-	Validated	-	-	-	N/A
Genor health estab priori	ator 1: mics in ncare is lished as a ty at nal/regional	0%	7%	93%	-	Validated	-	-	-	N/A
ltem		Rating Not adequa	by % of e	xperts Adequate	Comments	Decision after Round 1	Rewording proposal	Agree %	Comments	Decision after Round 2
MLs	1. Genomics in healthcare is not included in national/reg ional health plans 2. Inclusion of genomics in healthcare in relevant national/reg ional health	0%		100%	-	Validated		-	-	N/A





plans is				
under				
discussion				
3. Genomics				
in				
healthcare				
is included				
in relevant				
national/reg				
ional health				
plans				
4. Genomics				
in				
healthcare				
is				
implemente				
d as part of				
national/reg				
ional health				
and other				
relevant				
plans (e.g.				
education or				
research)				
5. Genomics				
in				
healthcare				
is				
implemente				
d in health				
and other				
relevant				
plans, and is				
periodically				
evaluated				
for				
optimization				
, taking into				
account				



#### Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



	novel developmen ts at the internationa l level.									
ltem		Rating Disagree ment	by % of Neutra l		Comments	Decision after Round 1	Rewording proposal	Agree %	Comments	Decision after Round 2
Subd Strate	omain 3: egy	0%	0%	100%	-	Validated	-	-	-	N/A
is a natio strate genor healt a cos	ementation	7%	0%	93%	•There is a national/regio nal strategy for genomics in healthcare with an implementatio n plan *with identified resources*. reworded accordingly. The options to be.	Validated	-	-	-	N/A
ltem		Rating	by % of	experts	Comments	Decision after	Rewording	Agree	Comments	Decision after
item		Not adequa	ate	Adequate	comments	Round 1	proposal	%	Comments	Round 2
MLs	1. No genomics in healthcare strategy with costed implementa tion plan 2. A strategy for	14%		86%	<ul> <li>See my previous answer.</li> <li>I believe the "costed implementatio n aspect" should be refunded to</li> </ul>	Validated with rewording	<ol> <li>No genomics in healthcare strategy with costed implementati on plan</li> <li>A strategy for genomics in healthcare</li> </ol>	-	-	N/A





genomics in		costed and	with costed		
healthcare			implementati		
		budgeted (or			
with costed		at least	on plan is		
implementa		partially	under		
tion plan		budgeted).	discussion		
under			3. A costed		
discussion			implementati		
3. A costed			on plan for		
implementa			genomics in		
tion plan for			healthcare is		
genomics in			developed		
healthcare			and approved		
is developed			4. A		
and			national/regi		
approved			onal strategy		
4. The			for genomics		
national/reg			in healthcare		
ional			is under		
strategy for			implementati		
genomics in			on		
healthcare			5. A		
is under			national/regi		
implementa			onal strategy		
tion			for genomics		
5. The			in healthcare		
national/reg			is		
ional			implemented		
strategy for			, with		
genomics in			monitoring		
healthcare			and long		
is			term		
implemente			resources		
d with			and aligned		
monitoring			with		
and			European		
long-term			and		
-			international		
resources					
			strategies		





29

 Table 2: Descriptive results for Domain II and respective sub-sections

	_	Round 1					Round 2	
ltom	Rating by % of experts		- Comments	Decision after	Rewording	Agr ee	Comments	Decision after
Item	Not Relevant	Relevant		Round 1	proposal	%	Comments	Round 2
Domain II: Investment and economic model	7%	93%	• Too many items on cost-effectivene ss: HTA, Cost-effectivene ss model, and Societal (patient/citizen) benefits, all indicate the same aspects. Also framework and model are very close to each other. Finally, this should include tests and treatment. I would use only one indicator: "Framework for cost-effectivene ss" - "There is a specified framework to model the societal benefits and costs of genomic tests and treatments, e.g. HTA".	Validated	-	-	-	N/A
ltem	Rating I	by % of experts	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2



Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



	Disagree ment	Neut ral	Agreem ent						
Subdomain 1: Investment	0%	7%	93%	-	Validated	-	-	-	N/A
Indicator 1: There is public funding for genomics in healthcare	21%	14%	64%	•The maturity levels imply an all or nothing approach. And also do not take into account government structures where there may be a shared costing between federal and state governments. This is the case in Some genetic testing (e.g. for childhood syndromes and intellectual disability) is covered by the federal government. Whereas other testing is at the discretion of the state or the hospital. SO depending on the condition - one could answer anything from 1-5.In addition - much testing is still in the realm of research (eg new	Reformul ated	There is an investment plan at the national and/or regional levels for genomics in healthcare, with public or mixed public-private funding models	93%	Does the investment plan refer to investments only or also running actions? The first option is clearly limited and this should obviously cover also maintenance of the operations. Could this be clarified as "investment and funding plan"?	Validated



Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



			50% of undiagnosed cases). • the most important is that there is sustainable funding rather than being only qualified as "public" as this could be suppressed by the next government! Donation or foundation funding might also function well if sustainable and non profit. • public funding phrase implies a money flow model. I think this should be phrased as a healthcare system compatible funding. Basically, reimbursement models are fine.					
ltem	Rating I Not adequate	by % of experts Adequate	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
ML 1. There is no	14%	86%	•There could be a level stating	Validated with	1. There is no established	-	-	N/A





establis	shod	"under	rewordin	investment		
	sneu					
public		development" or	g	plan at the		
funding		"under		national or		
genomi	ICS	discussion"		regional		
in				levels for		
healthc		<ul> <li>The fact that</li> </ul>		genomics in		
2. Publ	ic	there is no		healthcare		
funding	g for	public funding		2. An		
genomi	ics	does not		investment		
in		necessarily mean		plan for		
healthc	are	low maturity		genomics in		
is		-		healthcare at		
allocate	ed			the national		
locally				and/or		
(e.g. at				regional		
hospita				levels is under		
level)				development.		
3. Ther	o ic			3. There is a		
	eis			national		
a	1/1					
nationa				and/or		
egional				regional		
investm				investment		
plan fo				plan for		
genomi	ics			genomics in		
in				healthcare		
healthc	are			that is mostly		
that is				dedicated to		
mostly				setting up		
dedicat	ted			infrastructure		
to setti	ing			4. There is a		
up	-			national		
infrastr	ruct			and/or		
ure				regional		
4. Ther	e is			investment		
a				plan for the		
nationa	al/r			regular		
egional				operational		
investr				costs of		
plan for				genomics in		
				healthcare		
the reg						
operati				(for specific		
l costs				tests e.g. for		
genomi	ICS			rare diseases		
in				diagnostics or		
healthc	care			specific		





(e.g. rare diseases diagnostics , cancer treatment) 5. There is a national/r egional investment plan for genomics in healthcare that incorporat es innovation according to opportuniti es and internation al developme nts						cancer treatments) 5. There is a national and/or regional investment plan for genomics in healthcare that incorporates innovation according to opportunities and international developments			
ltem	Rating I	oy%ofe	experts	Comments	Decision after	Rewording	Agr ee	Comments	Decision after
item	Disagree ment	Neut ral	Agreem ent	comments	Round 1	proposal	%	comments	Round 2
Subdomain 2: Access and reimbursement	0%	0%	100%	-	Validated	-	-	-	N/A
Indicator 1: Genomic tests have a reimbursement or no-cost access plan at national/regiona l level	14%	7%	79%	<ul> <li>As above - depends on the condition or set of conditions</li> <li>No cost I find clunky wording.</li> </ul>	Reformul ated	There is a framework for reimbursemen t or no-cost access plans for genomic tests, at the national	100 %	-	Validated



Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



34

							and/or regional levels			
	ltem	Rating by % of experts			- Comments	Decision after	Rewording	Agr ee	Comments	Decision after
		Not adequate	Adequate			Round 1	proposal	%		Round 2
ML	1. No central reimburse ment or no-cost access plan for genomic tests 2. Reimburs ement or no-cost access plans for genomic tests are developed and approved 3. Reimburs ement or no-cost access plans for genomic tests are operationa lized 4. Reimburs	23%	7	77%	<ul> <li>There could be a level stating "under development" or "under discussion"</li> <li>No central reimbursement may again not mean low maturity, there may be a law/policy for disease specific/patient specific reimbursement, or even distributed models. This may even mean higher level of maturity</li> <li>See previous comments</li> </ul>	Reformul ated	1. No framework for reimbursemen t or no-cost access plans for genomic tests 2. A framework for reimbursemen t or no-cost access plans for specific genomic tests is under development 3. A reimbursemen t framework or no-cost access plans for specific genomic tests are developed, approved and operationalize d, with disease or patient-specifi ic models 4. A reimbursemen t framework or no-cost access plans for specific genomic tests are developed, approved and operationalize d, with disease or patient-specifi ic models 4. A	93%	If the maturation level 5 (Reimbursement or no-cost access plans for specific genomic tests are fully implemented, periodically evaluated and optimised, with plan for adoption of novel tools and technologies) implies that periodic evaluation and plan to adopt new tools also includes evaluation which disease entities and/or phenotypes (such as pharmacogenetics) should be covered by the plan, I AGREE, If not or if not clear, I think that aspect should be added	Validated



**Beyond One Million Genomes** B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



Item Subdomain 3: Health Technology Assessment (HTA) framework	Disagree ment 7%	Neut ral	Agreem ent 71%	•See my comment on combining the three cost-effectivene ss subdomains.	after Round 1 Reevalua te	Rewording proposal	ee % 93%	Comments The three economic model subdomains can be combined using C-E assessment subdomain as the basis. Still struggling to understand the fundamental difference in between HTA and C-E frameworks and why societal benefits wouldn't be included	after Round 2 Validated
ed in national/r egional healthcare systems 5.Reimburs ement or no-cost access plans for genomic tests are fully implement ed, periodicall y evaluated and optimised, with plan for adoption of novel tools and technologi es	Rating	by % of e	wherts		Decision	genomic tests are fully implemented in national and/or regional healthcare systems 5. A reimbursemen t framework or no-cost access plans for specific genomic tests are fully implemented, periodically evaluated and optimised, with plan for adoption of novel tools and technologies	Agr		Decision

Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



ltem	Rating by % of experts Not Adequate		Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2	
Indicator 1: There is a specific HTA framework for genomic testing in healthcare	14%	22%	64%	<ul> <li>See my comment on combining the three cost-effectivene ss subdomains.</li> <li>it does not need to be specific (you might imagine other domains where the same framework applies) but it needs to be well adapted and easily applicable to genomics</li> </ul>	Reformul ated	There is a HTA framework to assess genomic tests in healthcare	93%	I don't think there is a HTA framework but NHS England are using Commissioning Through Evaluation via the Genomic Laboratory Hubs to bring new tests to evidence level.	Validated
								in them by definition. The other option is to have one subdomain "economic assessment" with three indicators. See my proposal under the C-E subdomain. Then in Domain II we would have three subdomains: - Investment and funding - Access and reimbursement - Economic evaluation	





								1	
	1. No central HTA framework for genomic			•There could be a level stating "under development" or "under discussion"		1. No HTA			
ML s	testing 2. HTA framework for genomic testing is developed and approved 3. HTA framework for genomic testing is operationa lized 4. HTA framework for genomic testing is implement ed in healthcare system 5. HTA framework is implement ed, periodicall y evaluated and optimised, with plan for adoption of novel	29%	71%	<ul> <li>need for follow up, development and update not considered</li> <li>The options need to be adjusted if the three cost-effectivene ss subdomains are combined as suggested. The best staring point is the options in the c-e subdomain, which might need to be slightly adjusted.</li> <li>There seems to be an error in the survey. From the MLM framework for this subdomain - should read No central HTA framework for genomic testing HTA framework for genomic testing is developed and approved</li> </ul>	Reformul ated	framework for genomic testing 2. HTA framework for genomic testing is under development 3. HTA framework for genomic testing is developed and approved 4. HTA framework for genomic testing is implemented in healthcare system 5. HTA framework is implemented, periodically evaluated and optimised, with plan for adoption of novel tools and technologies	100 %		Validated



B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



tools and technologi es				HTA framework for genomic testing is operationalized HTA framework for genomic testing is implemented in healthcare system HTA framework is implemented, periodically evaluated and optimised, with					
				plan for adoption of novel tools and technologies Which I do think is adequate.					
ltem	Rating Disagree ment	oy % of e Neut ral	experts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
Subdomain 4: Cost-effectiven ess Model	22%	14%	64%	See my comment on combining the three cost-effectivene ss subdomains. I understand that I should express here the situation of our health care system n This sub domain in my opinion is not needed- the	Reformul ated	Cost-effective ness assessment framework	93%	See my comment on HTA to combine the three indicators.	Validated





				cost-effectivene ss model used by a particular health system will be defined by them in the context of how they assess/evaluate cost-effectivene ss for healthcare interventions as part of their decision making. To imply that a specific c/e model needs to be in place to implement genomic medicine is incorrect in my opinion.					
Indicator 1: There is a cost-effectivene ss model for use of genomic tests in healthcare	36%	7%	57%	<ul> <li>See my suggestion for the indicator formulation for a combined cost-effectivene ss subdomains.</li> <li>As above - this varies according to the condition. In - it is rigorous in single gene disorders. But less so in terms of testing for cancer.</li> <li>why limit it to effectiveness; cost benefit could also work</li> </ul>	Reformul ated	There is a framework for cost-effective ness assessment of genomic tests	93%	If three subdomains combined, then this could be reworded as follows: "There is a framework for economic assessment of genomics in healthcare, such as HTA or cost-effectiveness of tests and treatments and including benefit to the society".	Validated



B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



				instead of cost effectiveness; one of the two could be a good domain and indicator; but I am not an economist so disregard if not feasible! •See previous comment.					
ltem		Rating b Not adequate	oy % of experts Adequate	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
ML s	1. No cost-effect iveness model 2. Cost-effect iveness model is developed and approved 3. Cost-effect iveness model is under implement ation as pilots 4. Cost-effect iveness model is implement ed in healthcare systems	36%	64%	<ul> <li>There could be a level stating "under development" or "under discussion"</li> <li>There are many different scenarios when genomics can be used in healthcare.</li> <li>Some are the same as before (traditional clinical genetics) but many are completely new, i.e. genomics can now be integrated in the diagnostic workup for completely new disease groups across more or</li> </ul>	Reformul ated	1. There is no framework for cost-effective ness assessment of genomic tests 2. A framework for cost-effective ness assessment of genomic tests is under development 3. A framework for cost-effective ness assessment of specific genomic tests in the healthcare context are under implementati on as pilots	93%	There is still confusion in this subdomain. It is fine to ask whether a health system has a framework for cost-effectiveness assessment but the maturity levels are unhelpful. There is also the focus on cost-effectiveness assessment. It is unlikely to be possible nor desirable to undertake full cost-effectiveness evaluation for all genomic tests that are implemented. Health systems will need to prioritise which genomic tests will need this. I still believe this subdomain can be	Validated





41
----

nationally		less all of		4. A		removed. There is a	
or		clinical medicine		framework for		great overlap with	
regionally		(personalised or		cost-effective		the HTA subdomain.	
5.		precision		ness		the first subdomain.	
J. Cost-effect		medicine). More		assessment of			
iveness		than one model		specific			
model is		will thus be		genomic tests			
implement		needed.		is			
ed,		needed.		implemented			
periodicall		•The maturity		in healthcare			
		levels may need		systems at			
y evaluated		to be slightly		the national			
		adjusted if the		and/or			
and optimised,		three		regional			
with plan		cost-effectivene		levels			
for		ss subdomains		5. A			
adoption		are combined as		framework for			
of novel		suggested.		cost-effective			
tools and		suggested.					
technologi		•Again this is		ness assessment of			
es		""all-or-nothing""		genomic tests			
es		. It does not		is			
		allow for there		implemented,			
		being		periodically			
		cost-effectivene		evaluated and			
		ss models in		optimised,			
		place for some		with plan for			
		disease areas (eg		adoption of			
		monogenic rare		novel tools			
		diseases) vs		and			
		others eg NIPT,		technologies			
		Some cancers,		technologies			
		pharmacogenomi					
		cs"					
		•Please see my					
		previous					
		comments - I					
		think this					
		subdomain is not					
		required.					
			Decision	Rewording	Agr		Decision
ltem	Rating by % of experts	Comments	after	proposal	ee	Comments	after
			Round 1	proposal	%		Round 2



Beyond One Million Genomes



		Disagree ment	Neut ral	Agreem ent						
Subdomain 5: Societal (patient/citizen ) benefits		21%	0%	79%	<ul> <li>See my comment on combining the three cost-effectivene ss subdomains.</li> <li>Please see my comments on c/e model - so it applies to these as well as these are explicitly linked to C/E models</li> </ul>	Reevalua te	-	93%	See my comment on HTA to combine the three indicators or put them under one subdomain.	Validated
Soci are ecor mod	cator 1: etal benefits integrated in romic lelling for omics	21%	0%	79%	See my comment on combining the three cost-effectivene ss subdomains. See previous comment.	Reformul ated	Societal benefits are considered in economic modelling for genomic medicine	100 %	-	Validated
	ltem	Rating by % of experts		Comments	Decision after	Rewording	Agr ee	Comments	Decision after	
		Not adequate	Ade	equate		Round 1	proposal	%		Round 2
ML s	1. Societal benefits are not considered in economic models for genomics in healthcare 2. Societal benefits	23%		77%	•The options need to be adjusted if the three cost-effectivene ss subdomains are combined as suggested. The best staring point is the options in the c-e subdomain, which might	Reevalua te	-	100 %	-	Validated





are	need to be			
quantified	slightly			
in	adjusted.			
economic				
models for	<ul> <li>Need better</li> </ul>			
genomics	definition of			
in	what is actually			
healthcare	meant by the			
3. Societal	"integration of			
benefits	societal benefits			
are	into the			
integrated	economic			
in	model". Not			
economic	clear to the			
models for	non-expert in			
specific	health			
genomic	economics.			
tests	Perhaps expand			
4. Societal	the definition of			
benefits	societal benefits			
are	e.g. improved			
integrated	quality of life,			
in global	benefit of			
genomics	"knowing",			
economic	equity of access			
models for	- all of which do			
regional or	not have a			
national	"direct"			
healthcare	economic			
systems	benefit."			
5. Societal				
benefits	•Please see my			
are	previous			
integrated	comments			
in global				
genomics				
economic				
models for				
regional or				
national				
healthcare				
systems				
and				
optimised				
for novel				



B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



B1MG — D5.1	
B1MG maturity level model and country-specific alignment within the mode	

44	

tools and technologi				
es				

N/A: Not Applicable.





45

Table 3: Descriptive results for Domain III and respective sub-sections

		Round	1			Round 2			
ltem	Rating by % of experts			Comments	Decision after	Rewording	Agre	Commonts	Decision
item	Not Relevant	Rele	evant		Round 1	proposal	e %	Comments	after Round 2
Domain III: Legislation and policy	7%	9	13%	•There are far too many subdomains in this section. Several could be combined. -Data protection and consent -Confidentia lity and preventing misuse. Do we even need confidentiali ty as it is a common issue for all healthcare. - Data reuse and sharing - Research integrity and ethics. No proposals at this stage on possible wording.	Validate d with rewordin g	Domain III: Ethics, Legislation and policy	-	-	N/A
ltem	Rating t Disagree ment	oy % of ex Neut ral	xperts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2



Beyond One Million Genomes



 To be combined to read: Data Validate Subdomain 1: 86% 7% 7% N/A --Data protection d protection \*and consent\* •To be combined: There are norms to Indicator 1: There protect and are norms to ensure the lawful, fair protect and ensure the lawful, and Validate 7% 7% 86% N/A --d fair and transparent transparent processing processing of of personal personal data data \*and obtaining the consent adapted to genomics\*. Rating by % of experts Decision Decision Rewording Agre after after Comments Comments ltem proposal e % Adequate Not Round 1 Round 2 adequate 1.Norms (e.g. legislatio Need to have an n, policies, option as to professio whether the nal existing regulatio Validate norms are MLs 7% 93% N/A ns, codes d adequate of and conduct) appropriate do not (eg the exist quality of 2.Norms the norm) are impleme nted but



**Beyond One Million Genomes** 

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



insufficie nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are impleme nted and consisten tly enforced 5.Norms are impleme nted, enforced and fit-for-pu rpose									
Tpose	Rating	Rating by % of experts			Decision				Decision
ltem	Disagree	Neut	Agreem	Comments	after	Rewording proposal	Agre e %	Comments	after
	ment	ral	ent		Round 1	proposal	C //		Round 2
Subdomain 2: Quality of patient care involving genetic/genomic testing	14%	0%	86%	•To be combined and read: Quality *and confidentiali ty* of patient care involving genetic/gen omic testing	Validate d	-	-	-	N/A
Indicator 1: There are norms ensuring the quality	21%	0%	<b>79</b> %	•When combined, to read: There are	Reformul ated*	There are norms ensuring the quality <b>of</b> genetic/	-	-	N/A

B1MG — D5.1

Beyond One Million Genomes

B1MG maturity level model and country-specific alignment within the model



genetic/genomic testing services (e.g. professional codes and self-regulatory bodies)				norms ensuring the quality *and confidentiali ty* of genetic/gen omic testing services (e.g. professional codes and self-regulato ry bodies) •just add "of" (quality of genomic testing)		genomic testing services (e.g. professional codes and self-regulatory bodies)			
		Rating b Not adequate	by % of experts Adequate	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
MLs	1.Norms (e.g. legislatio n, policies, professio nal regulatio ns, codes of conduct) do not exist 2.Norms are impleme nted but insufficie nt in scope 3.Norms are	7%	93%	•I believe this is too specific	Validate d	-	-	-	N/A



B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



impleme nted but not yet consisten tly enforced 4. Norms are impleme nted and consisten tly enforced 5. Norms are impleme nted, enforced and fit-for-pu rpose									
ltem	Rating b Disagree ment	by % of e Neut ral	xperts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
Subdomain 3: Special rules for vulnerable groups (e.g. minors, adults with diminished capacity)	14%	7%	79%	<ul> <li>Counselling to be added: Special rules</li> <li>*and counselling* for vulnerable groups (e.g. minors, adults with diminished capacity)</li> <li>Should you also think about diversity in terms of ethnicity/re</li> </ul>	Reformul ated	Special rules and counselling for vulnerable groups	100 %	-	Validated





ltem	Rating I Not adequate	by % of e	experts equate	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
Indicator 1: There are special rules to ensure that vulnerable groups have access to genetic/genomic testing, with appropriate protections to avoid their exploitation	14%	7%	79%	<ul> <li>To read:</li> <li>To read:</li> <li>There are</li> <li>special rules</li> <li>to ensure</li> <li>that</li> <li>vulnerable</li> <li>groups have</li> <li>access to</li> <li>genetic/gen</li> <li>omic</li> <li>testing, with</li> <li>appropriate</li> <li>*counselling</li> <li>and*</li> <li>protections</li> <li>to avoid</li> <li>their</li> <li>exploitation</li> <li>I would</li> <li>suppress "to</li> <li>avoid their</li> <li>exploitation"</li> <li>because it is</li> <li>too</li> <li>restrictive;</li> <li>may be if</li> <li>you want to</li> <li>specify</li> <li>reasons, "to</li> <li>fully respect</li> <li>their rights</li> <li>and</li> <li>especially</li> <li>avoid their</li> <li>exploitation"</li> </ul>	Reformul ated	There are special rules to ensure that vulnerable groups have access to genetic/genomic testing, with counselling and appropriate protections to fully respect their rights and avoid their exploitation	93%	-	Validated
				cent ancestry as well?					





	1.Norms			•There					
	(e.g.			could be a					
	legislatio			level stating					
	n,			"under					
	policies,			developmen					
	professio			t" or "under					
	nal			discussion"					
	regulatio								
	ns, codes			•I think					
	of			these norms					
	conduct)			should not					
	do not			be specific					
	exist			to genetic					
	2.Norms			data, but to					
	are			health data					
	impleme			and digital					
	nted but			health					
	insufficie			intervention					
	nt in			s/therapeuti					
	scope			CS					
	3.Norms	2201	770/		Reevalua		100		
MLs	are	23%	77%	•I think	te	-	%	-	Validated
	impleme			protection					
	nted but			of					
	not yet			vulnerable					
	consisten			groups					
	tly			should					
	enforced			mandatory					
	4.Norms			and					
	are			equitably					
	impleme			accessible					
	nted and								
	consisten								
	tly								
	enforced								
	5.Norms								
	are								
	impleme								
	nted,								
	enforced								
	and								
	fit-for-pu								
	rpose.								





		Rating b	by % of e	experts		Decision	Rewording	Agre		Decision
ltem		Disagree ment	Neut ral	Agreem ent	Comments	after Round 1	proposal	e %	Comments	after Round 2
Subdomair Consent to genetic/ge testing and genetic counselling	o enomic d	7%	7%	86%	•Combined with data protection	Validate d	-	-	-	N/A
Indicator 1 are norms appropriate consent is obtained ai counselling provided in relation to genetic/ge testing	: There to e nd g is	0%	7%	93%	-	Validate d	-	-	-	N/A
ltem		Rating b Not adequate	by % of e	equate	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
MLs (e le n, pr na re dc dc ex 2. ar im nt	olicies, rofessio al egulatio s, codes f onduct) o not xist .Norms	23%		77%	<ul> <li>There could be a level stating "under developmen t" or "under discussion"</li> <li>Consent should be universal and offer opportunity for research to all</li> <li>What is meant by</li> </ul>	Reevalua te	-	100 %	-	Validated





nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are impleme nted and consisten tly enforced 5.Norms are impleme nted, enforced and fit-for-pu				enforced in this context?					
Item	Disagree	by % of e	Agreem	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
Subdomain 5: Confidentiality, professional secrecy	7%	ral 7%	ent 86%	•Combined with Quality of care.	Validate d		-	-	N/A
Indicator 1: There are norms protecting the confidentiality of patient genetic/genomic test results, and clarifying where family members may have rights to	8%	8%	84%	• the formulation gives the impression that only family members are concerned; may be say "and	Reformul ated	There are norms protecting the confidentiality of patient genetic/genomic test results, and specifically clarifying where family members may have rights	100 %	-	Validated





access these results			specifically clarifying where family members may have rights to access these results"		to access these results			
ltem	Rating I Not	by % of experts Adequate	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
	adequate							
1.Norms (e.g. legislatio n, policies, professio nal regulatio ns, codes of conduct) do not exist 2.Norms are impleme nted but insufficie nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are	14%	86%	<ul> <li>There could be a level stating "under developmen t" or "under discussion"</li> <li>Confidentia lity should be universally respected</li> </ul>	Validate d		-	-	N/A





	impleme nted and consisten tly enforced 5.Norms are impleme nted, enforced and fit-for-pu rpose.									
		Rating by % of experts			Decision	Rewording	Agre		Decision	
ltem		Disagree ment	Neut ral	Agreem ent	Comments	after Round 1	proposal	e %	Comments	after Round 2
Subdor Preven mis-use genetic results	nting e of c/genomic	0%	7%	93%	-	Validate d	-	-	-	N/A
are nor genetic testing legitim purpose preven mis-use employ	ate es and	0%	7%	93%	-	Validate d	-	-	-	N/A
		Rating t	oy % of e	experts		Decision	Rewording	Agre		Decision
ltem		Not adequate	Ade	equate	Comments	after Round 1	proposal	e %	Comments	after Round 2
MLs	1.Norms (e.g. legislatioMLsn, policies, professio nal	23%		77%	•There could be a level stating "under developmen t" or "under discussion"	Reevalua te	-	100 %	-	Validated





regulatio	>			
ns, codes	generally			
of	this could be			
conduct)	a level in			
do not	most of the			
exist	questions.			
2.Norms				
are	<ul> <li>I believe</li> </ul>			
impleme	these norms			
nted but	should not			
insufficie	be			
nt in	addressed			
scope	separately.			
3.Norms	The idea			
are	that insurers			
impleme	and			
nted but	employers			
not yet	as "the bad			
consisten	guys" is not			
tly	always			
enforced	realistic, nor			
4.Norms	the best at			
are	time to			
impleme	foster			
nted and	societally			
consisten	use of what			
	comes out of			
tly enforced	genetic			
5.Norms				
	information,			
are	particularly			
impleme	as well see and know			
nted,				
enforced	that more			
and	and more			
fit-for-pu	other			
rpose.	"omics" are			
	equally			
	relevant			
	•Failure to			
	universally			
	address this			
	may lead to			
	reduced			



B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



i	fic alignment	within the I	model		57
	0				
	participant engagement				
	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments
	•Combined with the next: Health data reuse, *sharing* and innovation	Validate d	-	-	-
	•the notion of transparency , public information about the use of data and may be				

		Rating I	oy % of e	experts		Decision	Rewording	Agre	Commonts	Decision after Round 2
ltem		Disagree ment	Neut ral	Agreem ent	Comments	after Round 1	proposal	e%	Comments	
Subdor Health reuse a innova	and	7%	7%	86%	•Combined with the next: Health data reuse, *sharing* and innovation	Validate d	-	-	-	N/A
is a nat strateg promot researc innova associa protect allowin and fun process th/gen for reso	gy for ting health ch and tion, and ated data tion rules ng sharing rther sing of heal metic data earch or ng other	7%	7%	86%	• the notion of transparency , public information about the use of data and may be leave open the use for training and education should be considered, unless it is clear that this is Validated in "treating other patients"?	Validate d	-	-	-	N/A
ltem		Rating I	by % of e	experts	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
	1.Norms	adequate			•Again need					
MLs	(e.g. legislatio n, policies,	7%		93%	to be more specific about the quality of	Validate d	-	-	-	N/A





do not exist 2.Norms are impleme nted but insufficie nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are impleme nted and consisten tly enforced 5.Norms are impleme nted and consisten tly enforced 5.Norms are				which is different to being "inadequate in scope". This will apply across the whole domain.					
ltem	Rating I Disagree ment	by % of e Neut ral	xperts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2



B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



B1MG — D5.1 B1MG maturity level model and country-specific alignment within the model								
Subdomain 8: Data sharing	7%	0%	93%	•Validated in the previous.	Validate d	-		
				•facilitating rather than				

Data sharing				previous.	u				
Indicator 1: There are norms promoting genomic data sharing by researchers/healt hcare providers	23%	0%	77%	<ul> <li>facilitating rather than promoting; and also the internationa l dimension could be introduced somewhere, as data sharing can be organised locally/natio nally but the facilitation of internationa l data sharing is important</li> <li>Needs further specification . There are norms promoting appropriate and legitimate genomic data sharing by researchers/ healthcare providers".</li> </ul>	Reformul ated	There are norms facilitating genomic data sharing by researchers and/or healthcare providers, at the national and international levels	100 %	- -	Validated





-

-

N/A

					model of data movement for some people secondary use of healthcare genomics for research is more open.					
ltem		Rating b Not adequate			Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
(e. leg n, po pro na reg ns, of co do ex 2.1 MLs are im nto sco do ex 2.1 MLs are im nto sco do ex 2.1 MLs are im nto sco the sco the sco do ex 2.1 MLs are im nto sco do ex 2.1 MLs are sco do ex 2.1 MLs are sco do ex 2.1 MLs are sco do ex 2.1 MLs are sco do ex sco do ex 2.1 MLs are sco do ex sco ex sco do ex sco do ex sco do ex sco ex sco ex sco do ex sco do ex sco do ex sco ex sco ex sco ex sco do ex sco ex sco do ex sco do ex sco ex ex sco ex sco ex ex sco ex sco ex sco ex sco ex sco ex sco ex sco ex sco ex sco ex e ex ex ex ex sco ex ex ex ex sco ex ex sco ex sco ex sco ex ex sco ex sco ex sco ex sco ex sco ex co co ex sco ex sco ex sco ex sco sco sco sco sco ex sco sco sco sco sco sco s sco s s s sco sco	blicies, rofessio al gulatio s, codes onduct) o not kist Norms re mpleme ed but sufficie t in nope Norms re mpleme ed but sufficie t in sufficie t in sufficie t in sope	0%	100	%	-	Validate d	-	-	-	N/A





are impleme nted and consisten tly enforced 5.Norms are impleme nted, enforced and fit-for-pu rpose.									
ltem	Rating I Disagree	by % of e	experts Agreem	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
Subdomain 9: Research Integrity	<u>ment</u> 14%	7%	ent 79%	To be combine and read: Research integrity *and ethics*	Reevalua	-	100 %	-	Validated
Indicator 1: There are norms and processes ensuring the ethical and scientific integrity of genomic research	14%	7%	79%	To read as combined: There are *ethical and scientific integrity* norms and processes *(and possibly bodies) adapted to multi-centre genetic and* genomic research •I agree on the substance;	Reformul ated	There are norms and processes ensuring the ethical practice and scientific integrity of genomic research	100 %	-	Validated





					but the formulation would be better if you say "There are norms and processes ensuring the ethical practice and scientific integrity of genomic research" (add practice or exercise or equivalent as the ethical integrity of research sounds a bit strange)					
ltem		Rating b	by % of expe Adequ		Comments	Decision after	Rewording proposal	Agre e %	Comments	Decision after
		adequate	Adequ	ale		Round 1				Round 2
MLs	1.Norms (e.g. legislatio n, policies, professio nal regulatio ns, codes of conduct) do not exist 2.Norms are	7%	93%	6	•Integrity should be universal	Validate d	-	-	-	N/A





impleme nted but insufficie nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are impleme nted and consisten tly enforced 5.Norms are impleme nted, enforced and fit-for-pu rpose.									
ltem	Rating I Disagree ment	by % of e Neut ral	xperts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
Subdomain 10: Coordinated research ethics oversight	7%	7%	86%	•Combined with the previous	Validate d	-	-	-	N/A
Indicator 1: There is a national research ethics committee or network to effectively and efficiently oversee the conduct of	0%	7%	93%	-	Validate d with rewordin g	There is a national (or regional if appropriate) research ethics committee or network to effectively and	-	-	N/A





multicen genetic/ studies	ntre genomic						efficiently oversee the conduct of multicentre genetic/genomic studies			
ltem		Rating b Not adequate			Comments	Decision after Round 1	Rewording proposal	Agre e %	Comments	Decision after Round 2
MLs	1.Norms (e.g. legislatio n, policies, professio nal regulatio ns, codes of conduct) do not exist 2.Norms are impleme nted but insufficie nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are impleme nted and consisten tly	29%		71%	<ul> <li>It is likely that there are national laws and regulations in place, but ethical committees may be local and not national/reg ional, and may not have common interpretatio n of regulations. There may not be one authority from who to apply ethical permits for national studies. Local vs national ethical committees should be Validated as options when</li> </ul>	Reformul ated	1. A framework for national or regional research ethics committee to oversee multicentre genetic/genomic studies does not exist 2. A framework for national or regional research ethics committee to oversee multicentre genetic/genomic studies is under development 3. A framework for national or regional research ethics committee to oversee multicentre genetic/genomic studies exists, but is not consistently enforced 4.A framework for national or	100 %		Validated





enforced		measuring	regional		
5.Norms		maturity.	research ethics		
are			committee to		
impleme		<ul> <li>Although I</li> </ul>	oversee		
nted,		don't	multicentre		
enforced		necessarily	genetic/genomic		
and		agree on a	studies is		
fit-for-pu		""dedicated""	implemented		
rpose.		centre for	and consistently		
		genetics/ge	enforced		
		nomics	5. A framework		
		studies - i	for national or		
		think there	regional		
		such be a	research ethics		
		institution/b	committee to		
		ody or	oversee		
		network for	multicentre		
		multicentric	genetic/genomic		
		biomedical	studies is		
		research	implemented,		
		(including	enforced and fit		
		genomics), I	for purpose		
		think the			
		existence of			
		Norms and			
		their level			
		of			
		implementat			
		ion and			
		fitness is not			
		the best			
		indicator for			
		maturity of			
		"the			
		existence" of			
		a national			
		research			
		ethics			
		committee,			
		or			
		network			
		RATHER its			
		Capacity, its			
		level of			
		internal			





					organisation and power for norm settling, conflict resolution and the SPEED of decision making and its participator y nature. • National ethics may need to be regional but this must be consistent • here I would use the word "framework" rather than "norms"					
ltem		-	by % of e		Comments	Decision after	Rewording	Agre	Comments	Decision after
		Disagree ment	Neut ral	Agreem ent		Round 1	proposal	e %		Round 2
Subdom Biobank		0%	0%	100%	-	Validate d	-	-	-	N/A
are norm addressii accredit. registrat supervisi secure si and resp use of hu	ing the action, tion, ion, torage, ponsible	7%	0%	93%	•I would add "exchange" or "sharing" or specify it is Validated in the "responsible use, as the sharing chapter	Validate d with rewordin g	There are norms addressing the accreditation, registration, supervision, secure storage, and responsible use (including exchange and sharing) of	-	-	N/A





				before only		human biological			
				address data		samples			
		Rating b	oy % of experts		Decision	Rewording	Agre		Decision
ltem		Not adequate	Adequate		after Round 1	proposal	e%	Comments	after Round 2
MLs	1.Norms (e.g. legislatio n, policies, professio nal regulatio ns, codes of conduct) do not exist 2.Norms are impleme nted but insufficie nt in scope 3.Norms are impleme nted but not yet consisten tly enforced 4.Norms are impleme nted and consisten tly enforced 5.Norms are	7%	93%	•This should be universal.	Validate d	-	-	-	N/A





68	
----	--

impleme				
nted,				
enforced				
and				
fit-for-pu				
rpose.				

\*Despite classified as "Reformulated", this item was not included in Round 2 as the only comment asked for the introduction of the word "of" missing in the previous phrasing; N/A: Not Applicable.





69

Table 4: Descriptive results for Domain IV and respective sub-sections

		Round	1		Round 2			Round 2	
ltem	Rating	by % of e	experts	Comments	CommentsDecision after Round 1Rewording proposalAgr ee %CommentsDeci a Round-ValidatedCommentsDecision after Round 1Rewording proposalAgr ee %CommentsDecision after Round 1•Why is this needed more than for any other innovative area of medicine? Awareness yes, but general literacy programmes should beImage: CommentsImage: CommentsDecision after Rewording proposalAgr ee ee %CommentsDecision after Round 1			Comments	Decision after
	Not Relev	ant	Relevant			Round 2			
Domain IV: Public awareness and acceptance	0%		100%	-	Validated	-	-	-	N/A
ltem	Rating	by % of e	experts	Commonte		Rewording	-	Commonte	Decision after
item	Disagree ment	Neutra l	Agreem ent	Comments	Round 1 Proposal	proposal		Comments	Round 2
Subdomain 1: Awareness	14%	0%	86%	• Why is this needed more than for any other innovative area of medicine? Awareness yes, but general literacy programmes should be through formal education systems. This should not be confused with the necessary information requirements for the public to make decisions and access genomic medicine	Validated	-	_	-	N/A



Beyond One Million Genomes



Indicator 1: There are literacy programmes or campaigns on genomic medicine	29%	0%	71%	services. Suggest this is rewritten to reflect this point. • To increase the equality, there could be an indicator measuring how well educational programs reach of minority populations • This should focus on surveying the situation, campaigning would then be the third subdomain. Suggestion: There are surveys on literacy on genomic medicine among the population and professionals.	Reformul ated	There are literacy programmes or campaigns on genomic medicine with monitored impact on awareness	86%	-l am afraid l have not changed my mind on this sub domain - as previously stated. Why is this needed more than for any other innovative area of medicine? Awareness yes, but general literacy programmes should be through formal education systems. This should not be confused with the necessary information requirements for the	Validated
				surveys on literacy on genomic medicine among the population and		impact on		systems. This should not be confused with the necessary information requirements	





	2		5	0					
								to reflect this point. I think it remains important to distinguish information for individuals to access and use services safely and in an informed manner including genomic applications and that of general population literacy programmes - at the moment it reads as the latter.	
ltem		Rating by	% of expert	s Comments	Decision after	Rewording	Agr ee	Comments	Decision after
nem		Not adequat	e Adequ		Round 1	proposal	%	comments	Round 2
MLs	1. No 2. Literacy programmes or campaigns are available locally as a bottom up initiative, on particular topics 3. Strategy for literacy	21%	795	<ul> <li>If         <ul> <li>reformulated</li> <li>then ML 1.</li> <li>No.; ML 2.</li> <li>Literacy</li> <li>programs or</li> <li>campaigns a</li> <li>available</li> <li>locally as a</li> <li>bottom up</li> <li>initiative, or</li> <li>particular</li> <li>topics.; ML 3</li> <li>Stratage for</li> </ul> </li> </ul>	re Reformul ated	1. No 2. Literacy programmes or campaigns are available locally as a bottom up initiative, on particular topics 3. Strategy for literacy programmes or campaigne	86%	-Maturity level 5 is not easy understand and should be rephrased. -See earlier comments.	Validated



programmes or

Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724

Strategy for



or campaigns

campaigns is		literacy	targeting		
defined and		programs or	specific		
under		campaigns is	audiences is		
implementatio		defined and	defined,		
n		under	based on		
4. Strategy for		implementati	genomic		
literacy		on.; ML 4.	literacy		
programmes or		Strategy for	surveys, and		
campaigns is		literacy	under		
defined and		programs or	implementati		
widely		campaigns is	on		
implemented		defined and	4. Strategy		
at national		widely	for literacy		
level, with		implemented	programmes		
dedicated		at national	or campaigns		
funds		level, with	targeting		
5. Strategy for		dedicated	specific		
literacy		funds. 1. No;	audiences is		
programmes or		2. A survey is	defined and		
campaigns is		being	widely		
widely		planned; 3.	implemented		
implemented		Basic	, with		
at national		information	dedicated		
level, with		exists through	funds		
regular update		a survey ; 4.	5. Strategy		
of topics to		Several	for literacy		
include		ad-hoc	programmes		
innovation,		surveys have	or campaigns		
and with		been carried	is widely		
dedicated		out; 5. There	implemented		
funds		is a	, with regular		
		systematic	evaluation		
		programme	and		
		for regular	monitoring of		
		genomic	impact on		
		literacy	awareness,		
		surveys.	update of		
		-	topics to		
		<ul> <li>See previous</li> </ul>	include		
		comments	innovation,		
			and with		
		<ul> <li>I think this</li> </ul>	dedicated		
		model wont	funds		
		fit some			
		regions/place			





				s - I don't think national is the right term rather different audiences perhaps, and I wonder if there should be a clinical outreach audience as well					
ltem	Rating Disagree ment	by % of ex Neutra l	perts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
Subdomain 2: Acceptance	7%	0%	93%	•The subdomain and indicator is confusing. Acceptance is the wrong term to capture adequate awareness and being informed of what genomic medicine can provide in terms of clinical utility for an individual and a population. Please reconsider the subdomains and indicators.	Validated	-	-	-	N/A





### B1MG — D5.1 B1MG maturity level model and country-specific alignment within the model

with pa	ions are well	7%	7%	86%	•See previous comment	Validated	-	-	-	N/A
ltem		Rating by % of experts Not adequate Adequate		Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2	
MLs	1. No 2. Available locally as a bottom up initiative with specific associations 3. Strategy for engaging patient associations in genomic medicine issues is defined and under implementatio n 4. Strategy for engaging patient associations in genomic medicine issues is widely implemented at national level, with dedicated funds 5. Strategy for engaging patient associations in genomic	21%		79%	<ul> <li>Is engagement and awareness limited to patient advocacy groups. Need consideration of other audiences.</li> <li>See previous comments</li> <li>Again, I worry about patient associations being a very "Anglo" thing - I am not sure this maps to every country well, and I don't want the cohesion of - say - Finland's approach to healthcare delivery and care be penalised by</li> </ul>	Reevaluat e		100 %	-	Validated





issues is widely implemented at national level, with dedicated funds, regular monitoring and updates to include innovation				the way we frame this.					
ltem	Rating Disagree ment	by % of ex Neutra	perts Agreem ent	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
Subdomain 3: Communication to the general public	14%	0%	86%	• it could be specified that the communicatio n strategy integrates interactive tools as it seems to be only "information" and rather passive as it is formulated	Validated	-	-	-	N/A
Indicator 1: There is a communication strategy for genomic medicine	29%	14%	57%	•To increase the equality there could be an indicator how well the communicatio n strategy reaches the minority populations, which may be less educated and have a different trust level	Reevaluat e	-	100 %	-	Validated





					<ul> <li>This should be broadened: There is a communicatio n strategy for genomic medicine implemented through literacy programmes or campaigns."</li> <li>same the indicator could Validated tools for active involvement of the public</li> </ul>					
ltem		Rating b Not adequ	-	experts Adequate	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
MLs	1. No 2. Available locally as a bottom up initiative with specific target audiences 3. Global strategy for communication to the public is under development 4. Strategy for communication is widely	21%		79%	•Slight modification: ML 3. A strategy for communicatio n to the public is under development. ; ML 4. A strategy for communicatio n is widely implemented at national level, with	Reformul ated	1. No 2. Available locally as a bottom up initiative with specific target audiences 3. A global strategy for communicati on with the public is under development	100 %	-	Validated





the state of the s	a de altra de la d		
	funds."		
	•see my		
	previous		
	comment	widely	
communication		implemented	
is widely	•Same	, with	
implemented	comment, l	dedicated	
at national	worry about	funds	
level, with	"national"	5. A global	
dedicated	here and I	strategy for	
funds, regular	worry that	communicati	
monitoring and	the paths for	on with the	
updates to	communicatio	public is	
Validated	n and	widely	
innovation	responsible	implemented	
	societal	, with	
	behaviour is	dedicated	
	quite varied.	funds and	
		regular	
		monitoring,	
		and includes	
		tools for	
		active	
		involvement	
		of the public	
		minorities	
	is widely implemented at national level, with dedicated funds, regular monitoring and updates to Validated	at national level, with dedicated fundsfunds."5. Strategy for communication is widely•see my previous commentimplemented at national level, with dedicated funds, regular monitoring and updates to•Same communication mational the paths for communication mational the paths for communication monitoring and updates tovalidated innovationn and responsible 	at national level, with dedicated fundsfunds."strategy for communicati on with the previous communication5. Strategy for communication is widelyon with the previous commentwidely implemented dedicatedis widely implemented at national level, with-Same worry aboutwith dedicateddedicated dedicatedhere and l mational"strategy for strategy forfunds, regular monitoring and updates to Validated innovationmand memented worry that responsible societal dedicatedon with the societal societal dedicatedinnovationn and responsible societal dedicatedjuite varied.funds and regular monitoring, and includes tools for active involvement of the public ingenenal,

N/A: Not Applicable.



Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



Table 5: Descriptive results for Domain V and respective sub-sections

	lterr	Rati	ing by % o	of exp	perts	Comments	Decision after	
	ltem	Not Releva	ant		Relevant	Comments	Round 1	
	Domain V: Workforce skills and organization		0%		100%	-	Validated	
		Rati	ing by % o	of exp	erts		Decision after	
Item		Disagreemen t	I Neuu		Agreement	Comments	Round 1	
Subdomaiı	n 1: Education	14% 0%		86%	•Should this read: University education in medicine and health-related professions"	Validated		
Indicator 1: Genomics is integrated in general university <i>curricula</i> for medical doctors		7%	% 0%		93%	•There isn't any mandatory subject matter in Genomics in the Faculties of Medicine in - with a few exceptions	Validated	
ltem		Rating by % of			oerts	Comments	Decision after	
item		Not adequate		Adequate		comments	Round 1	
MLs	<ol> <li>No or ad hoc</li> <li>Needs assessed, gaps identified, training options under development</li> <li>Training available, under implementation</li> <li>Training available and widely implemented</li> <li>Training curricula regularly updated to incorporate novel technologies and tools</li> </ol>	7%		93%		•Life-long education of medical doctors on genome medicine could be Validated in these options or made a separate indicator	Validated	
	Item	Rati	ing by % o	of exp	perts	Comments	Decision after Round 1	



## Beyond One Million Genomes



### B1MG — D5.1 B1MG maturity level model and country-specific alignment within the model

79	
----	--

		Disagreemen t	Neutra	l Agreement		
	Genomics is integrated urricula for nurses	7% 0%		93%	•The same. No subject matters on the topic in -	Validated
ltem	ltem		ing by % of	experts	Comments	Decision after Round 1
		Not adequ	ate	Adequate		Round I
MLs 1. No or <i>ad hoc</i> 2. Needs assessed, gaps identified, training options under development 3. Training available, under implementation 4. Training available and widely implemented 5. Training <i>curricula</i> regularly updated to incorporate novel technologies and tools		0% 100;		100%	-	Validated
		Rating by % of experts				Decision after
	Item	Disagreemen t	Neutra	l Agreement	Comments	Round 1
	Indicator 3: Genomics is integrated in general curricula for pharmacists		7% 0%		•Not at all integrated as a subject matter even as optional	Validated
		Rati	ing by % of	experts	Community	Decision after
ltem		Not adequate		Adequate	Comments	Round 1
MLs	<ol> <li>No or <i>ad hoc</i></li> <li>Needs assessed, gaps</li> </ol>	0%		100%	-	Validated





identified, training options under development 3. Training available, under implementation 4. Training available and widely implemented 5. Training curricula regularly updated to incorporate novel technologies and tools Rating by % of experts Decision after Item Comments Round 1 Disagreemen Neutral Agreemen t Subdomain 2: Careers in genomic 7% 0% 93% Validated medicine Indicator 1: There are officially recognized professional titles and 7% 7% 86% Validated career paths for genomic medicine Rating by % of experts Decision after Item Comments Round 1 Not adequate Adequate 1. No workforce strategy or policy that recognizes genomic medicine professionals, and distribution of professionals is ad hoc 2. Strategy or policy for genomic medicine MLs professionals is 0% 100% Validated proposed and under review 3. Strategy or policy for genomic medicine professionals is approved and under implementation 4. Strategy or policy



**Beyond One Million Genomes** 

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



for genomic medicine professionals is implemented, with full recognition and acceptance of career paths 5. Professional titles and career paths for genomic medicine professionals are flexible and regularly updated to incorporate needs from novel						
technologies and tools	Rat	ing by % d	of exp	erts		Decision after
ltem	Disagreemen t	Neutr	al	Agreement	Comments	Round 1
Indicator 2: There are training programmes for genetic counselling	7%	7%		86%	• At least there are not official training courses, except some endorsed by the -	Validated
ltem	Rat	ing by % o	of exp	erts	Comments	Decision after
item	Not adequ	ate		Adequate	comments	Round 1





MLs	<ol> <li>No or ad hoc</li> <li>Needs assessed, gaps identified, training options under development</li> <li>Training graduates are available but not yet deployed</li> <li>Training graduates are deployed, but essential personnel gaps remain</li> <li>Sufficient numbers of training graduates are available to support evolving national/regional needs</li> </ol>	7%		93%	•Training available but insufficient in scope would be an alternative indicator.	Validated	
	lt	Rati	ng by % of	experts	Commente	Decision after	
	ltem	Disagreemen t	Neutral	Agreement	Comments	Round 1	
Indicator 3: There are life-long or continuing education programmes in genomic medicine for different healthcare professionals		7% 0%		93%	•Nor regularly stablished. Only optional	Validated	
		Rati	ng by % of	experts		Decision after	
ltem		Rati Not adequa		experts Adequate	Comments	Decision after Round 1	





	implemented 5. Training <i>curricula</i> regularly updated to incorporate novel technologies and tools					
		Rati	ing by % c	of experts		Decision after
	ltem	Disagreemen t	Neutr	al Agreement	Comments	Round 1
Subdomain 3: Policy makers		14%	0%	86%	•I am a bit doubtful of the usefulness of this question. In any case, I would reformulate it to read (also reverse the order - managers mentioned first): Healthcare managers and health policy makers"	Validated
for policy ma managers to genomic med	There are programmes akers and healthcare raise awareness on dicine and its for healthcare	7%	7%	86%	-	Validated
		Rati	ing by % c	of experts		Decision after
ltem		Not adequate		Adequate	- Comments	Round 1
MLs	<ol> <li>No or ad hoc</li> <li>Needs assessed, gaps identified, program options under development</li> <li>Programmes available, under implementation</li> <li>Fully functional implementation of programmes at national level</li> <li>Programmes are implemented and periodically evaluated for inclusion of novel tools and technologies</li> </ol>	7%		93%	•Not sure training is the correct term? As it is a fast evolving field - it is about raising awareness and keeping these key groups informed of developments and applications in genomic medicine - this is about live appropriate information dissemination.	Validated





### B1MG — D5.1 B1MG maturity level model and country-specific alignment within the model

84





Table 6: Descriptive results for Domain VI and respective sub-sections

		R	ound 1				R	ound 2	
ltem	Rating by % of experts			Comments	Decision After	Rewording proposal	Agr ee	Comments	Decision after
	Not Relev	ant	Relevant		Round 1	proposar	%		Round 2
Domain VI: Clinical organisation, infrastructure and tools	0%		100%	-	Validated	-	-	-	N/A
ltem	Rating b	oy % of Neut al	r Agree	Comments	Decision After Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
Subdomain 1: Information and Communications Technology (ICT) tools for clinical decision	14%	0%	86%	•I would focus here on *advanced* tools for genomics, and not include EHR or other normal healthcare tools. E.g. Use of advanced tools on genomics.	Validated	-	-	-	N/A
Indicator 1: There are ICT tools for clinical interpretation of genomic results implemented in public hospitals and clinics	21%	0%	79%	•Following from the subdomain, I would not Validated EHR (as in the tip) or other normal healthcare tools. E.g. Clinicians have access to and use of advanced (including AI-based) tools on genomics for clinical interpretation and decision-making.	Reformul ated	There are ICT tools supporting clinical interpretation of genomic results, clinical decision-maki ng and communicatio n with the patient implemented in public hospitals and clinics	93%	The basic e-health tools should not be enough, suggestion: "There are ICT tools supporting SPECIFICALL Y clinical interpretati on of genomic results,"	Validated



Beyond One Million Genomes



			<ul> <li>I agree but would add the dimension that the tools are not only for interpretation but Validated elements for communicating/ex plaining the results to patients; just interpretation is too restrictive</li> <li>Not in most of cases. Only very few exceptions</li> </ul>					
ltem	Rating by Not adequat	 xperts Adequate	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2





genomic medicine 5. ICT tools implemented and	
1. ICT tools not available 2. ICT tools available in selected hospitals, frequently associated with research projects 3. ICT tools under wider implementati on in healthcare systems following a strategy for genomic medicine       0%       100%       Validated       -       -         MLs       medicine medicine necided as part of national/regi onal health systems       0%       100%       -       Validated       -       -	N/A





		Disagree ment	Neutr al	Agree ment						
-	omain 2: lisciplinary	7%	0%	93%	•Few exceptions in the country	Validated	-	-	-	N/A
teams medic multic and in	tor 1: Clinical for genomic ine are disciplinary Iclude ICT and Idical experts	14%	0%	86%	•as you specify some elements of the interdisciplinarity (ICT and biomedical expert) I would also specify the presence of a psychology expert	Validated with rewordin g	Clinical teams for genomic medicine are multidisciplin ary and include ICT, biomedical and psychology experts	-	-	N/A
ltem		Rating t Not adequ	· 	experts Adequate	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2
MLs	1. Not available 2. Teams are assembled in some hospitals as a bottom up initiative, but not all areas are covered or necessary tools are available 3. Guidelines for assembling multidisciplin ary teams exist, and	0%		100%	-	Validated	-	-	-	N/A





there are				
referral				
networks at				
regional/loca				
l level.				
4. Guidelines				
for				
assembling				
multidisciplin				
mutualsciptin				
ary teams				
and referral				
networks are				
implemented				
at				
regional/nati				
onal level,				
aligned with				
a strategy for				
genomics in				
healthcare				
and with				
dedicated				
funding				
5.				
Multidisciplin				
ary teams				
are the norm				
for				
implementati				
on of				
national				
genomics in				
medicine				
strategy and				
the				
guidelines				
for their				
assembly and				
operation,				
and referral				
networks,				
are reviewed				
and				
optimised				
periodically				



# Beyond One Million Genomes

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



B1MG — D5.1 B1MG maturity level model and country-specific alignment within the model

	Rating b	by % of ex	operts		Decision	Rewording	Agr		Decision
ltem	Disagree ment	Neutr al	Agree ment	Comments	after Round 1	proposal	ee %	Comments	after Round 2
Subdomain 3: Turnover/uptake of novel tools and technology	14%	7%	79%	Could we simplify: Uptake of novel genomics technologies"     This subdomain	Reformul ated	Uptake of novel tools and technologies for genomics	100 %	-	Validated
Indicator 1: Adoption of novel technologies and software tools to support clinical decisions is fit-for-purpose	7%	7%	86%	•See previous comment	Validated	-	-	-	N/A
ltem	Rating b	by % of ex	operts	Comments	Decision after Round 1	Rewording proposal	Agr ee %	Comments	Decision after Round 2





	Not adequate	Adequate						
1. No or ad hoc2. Novel technologies and tools are selected and implemented locally (e.g. hospital, laboratory) 3. There are plans and processes for adoption of novel technologies and tools to support clinical decision making, but not widely implemented at regional/nati onal levels 4.Plans and processes for adoption of novel technologies and tools to support clinical decision making, but not widely implemented at regional/nati onal levels 4.Plans and processes for adoption of novel technologies and tools to support clinical decision making are centralised at the regional/nati onal levels, and aligned with a national	14%	86%	•Funding should be Validated in the maturity level options •See previous comment	Validated	-	-	-	N/A





strategy for genomics in healthcare 5.Plans and processes for adoption of novel technologies and tools to support clinical decision making are centralised at the regional/nati onal levels, and aligned with a national strategy for genomics in healthcare,									
international standards Item		by % of ex		Comments	Decision after	Rewording proposal	Agr	Comments	Decision after
	Disagree ment	Neutr al	Agree ment		Round 1	proposai	%		Round 2
Subdomain 4: Synergies with research	14%	7%	79%	• I agree generally but synergy is may be too demanding at the start; organised link with research might be more applicable without reaching at first a true synergy; may be add an indicator to specify if it is	Reevaluat e	-	100 %	_	Validated



Beyond One Million Genomes



					synergy yet or not yet! •I do not understand what is meant by this subdomain and indicator? Do you mean there is close collaboration between clinical services and academia?					
are pr establ integr	tor 1: There ocesses ished for the ation of the with research mes	7%	7%	86%	•See previous comment.	Validated	-	-	-	N/A
		Rating b	y % of	experts	Commente	Decision	Rewording	Agr	C	Decision
ltem		Not adequ	iate	Adequate	Comments	after Round 1	proposal	ee %	Comments	after Round 2
MLs	1. No or ad hoc 2. Implemented at a local level, depending on free will 3. Implemented at local and regional level according to a local strategy for integrating stakeholders and partnerships 4.	14%		86%	<ul> <li>See previous comment</li> <li>I think using the phrase "free will" is a bit odd here.</li> </ul>	Validated with rewordin g	1. No or ad hoc 2. Implemented at a local level, depending on individual initiative 3. Implemented at local and regional level according to a local strategy for integrating stakeholders and partnerships 4. Implemented	-	-	N/A





Implemented at national level with well established partnerships, support from public funds and dedicated budget 5. Implemented at national and international level with well established partnerships, periodically evaluated, support from public funds and dedicated budget						at national level with well established partnerships, support from public funds and dedicated budget 5. Implemented at national and international level with well established partnerships, periodically evaluated, support from public funds and dedicated budget			
	Rating b	by % of e	xperts		Decision	<b>.</b>	Agr		Decision
ltem	Disagree ment	Neutr al	Agree ment	Comments	after Round 1	Rewording proposal	ee %	Comments	after Round 2
Subdomain 5: Synergies with industry	14%	7%	<b>79%</b>	<ul> <li>same comment regarding the use of "synergy"; there may be other steps before reaching synergy</li> <li>The term integration is perhaps incorrect in health systems - collaboration,</li> </ul>	Reformul ated	Partnership with industry	100 %	-	Validated



Beyond One Million Genomes



effective partnerships are alternative terms to consider? As the significance and role of the industrial partnerships •I would add the differs "transparency" between element here as it There are countries, a can strongly effective better Indicator 1: There influence the partnerships indicator adhesion of the is integration of with would be Reformul stakeholders and 14% 7% **79**% public to 93% Validated stakeholders level of ated partnerships from collaboration with from the implementa the industry sector industry; may be in industry tion of a indicators? national sector strategy or See previous framework comment. for industrial partnerships and stakeholders Rating by % of experts Decision Decision Agr Rewording after after Comments Comments ltem ee proposal % Not adequate Adequate Round 1 Round 2 1. No or ad 1. No or ad hoc hoc 2. 2. See previous Implemented Implemented comment Validated at a local at a local with level. MLs 14% 86% N/A level, •I think the use of rewordin depending on depending on the phrase "free individual g free will will" is a bit odd initiative 3. 3. Implemented Implemented at local and at local and



**Beyond One Million Genomes** 

B1MG has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 951724



regional level	regional level
according to	according to a
a local	local strategy
strategy for	for integrating
integrating	stakeholders
stakeholders	and
and	partnerships
partnerships	from the
from the	industry
industry	sector
sector	4.
4.	Implemented
Implemented	at national
at national	level with
level with	well
well	established
established	partnerships,
partnerships,	according to a
according to	national
a national	strategy for
strategy for	integration of
integration	industry
of industry	stakeholders
stakeholders	5.
5.	Implemented
Implemented	with well
with well	established
established	national and
national and	international
international	partnerships,
partnerships,	according to a
according to	national
a national	strategy for
strategy for	integration of
integration	industry
of industry	stakeholders
stakeholders	

N/A: Not Applicable.





Table 7: Descriptive results for Domain VII and respective sub-sections

ltem	Rating	g by % of exp	erts	Comments	Decision after
item	Not Relevant Relevant		Comments	Round 1	
Domain VII: Clinical genomics guidelines and infrastructure	7%		93%	• "Sequencing/ genotyping infrastructure" would better fit the previous domain. The name of the 7th domain could be simply Clinical Genomic Guidelines"". A related question is whether we need ""clinical"" in the names of the two domains. I understand that it seeks to drive thinking towards clinical implementation but this is still rather rare. Thus ""genomic organisation, infrastructure and tools"" and ""Genomic guidelines"" could be better expressions.	Validated
ltem	Rating by % of experts			Comments	Decision after
item	Disagreement	Neutral	Agreement	Comments	Round 1
Subdomain 1: Sequencing/genotyping infrastructure	7%	7%	86%	•To be moved to the previous domain. The subdomain as such is ok.	Validated
Indicator 1: Genomic centres are established	7%	0%	93%	-	Validated
ltem	Rating	g by % of exp	erts	Comments	Decision after
	Not adequate	e A	dequate	Comments	Round 1
MLs 1. No 2. Genomic centres are local (e.g. hospital,			93%	•Again, this presupposes that organisational centres is the right model. I would	Validated



Beyond One Million Genomes



	laboratory) 3. Genomic centres infrastructure networks are under development, to include common working guidelines and shared policies 4. Genomic centres infrastructure networks are implemented at the regional/national levels, and operate under common guidelines and policies 5. Genomic centres infrastructure networks are implemented at the regional/national levels, and operate under common guidelines and policies and aligned with global standards				draw upon radiology as a discipline for this.	
	ltem	Rating	g by % of expe	erts	Comments	Decision after
		Disagreement	Neutral	Agreement		Round 1
Subdomain guidelines	2: Sequencing	0%	7%	93%	-	Validated
	: Guidelines for are defined	0%	7%	93%	-	Validated
	are defined		7% g by % of expe		-	Validated Decision after
			g by % of expe		- Comments	



Beyond One Million Genomes



3. Local level genomic sequence generation for clinical use is aligned with ISO lab accreditation/protocols 4. Genomic sequence generation is coordinated at regional/national level and aligned with ISO lab accreditation/protocols 5. Genomic sequence generation at regional/national level is governed in alignment with ISO accreditation/protocols, reviewed periodically, and in line with international standards							
	ltem		g by % of expe	erts	Comments	Decision after	
	item	Disagreement	Neutral	Agreement	comments	Round 1	
	3: Primary tics analysis	0%	0%	100%	-	Validated	
Indicator 1: Guidelines for genomic data analysis are defined		0%	0%	100%	-	Validated	
	ltom	Rating	g by % of expe	erts	Commonts	Decision after	
	ltem	Rating Not adequate		l erts lequate	Comments	Decision after Round 1	



Beyond One Million Genomes



regional/national level 4. Standardised genomic analysis guidelines are implemented at national level and reviewed periodically 5. Standardised genomic analysis guidelines are implemented at national level, reviewed periodically and aligned with global standards							
		Rating	g by % of expe	erts	<b>.</b> .	Decision after	
	Item		Neutral	Agreement	Comments	Round 1	
-	Subdomain 4: Structure of sequence-associated metadata		7%	93%	-	Validated	
metadata s	Indicator 1: Guidelines for sequence metadata structure to support clinical interpretation are established		7%	93%	-	Validated	
		Rating	g by % of expe	erts		Decision after Round 1	
	ltem	Not adequate	e Ao	lequate	Comments		
MLs	<ol> <li>No</li> <li>Guidelines to structure metadata to meet clinical use cases are defined locally (e.g. hospital, laboratory)</li> <li>Guidelines to structure metadata to meet clinical use cases are defined regionally/nationally</li> <li>Standardised guidelines to structure metadata to meet clinical use cases are implemented at the</li> </ol>	7%		93%	•Similar to previous answer, I think you can make explicit use of a phrase "such as GA4GH standards" here.	Validated	





national level and are reviewed periodically 5.International guidelines to structure metadata to meet clinical use cases are followed, implemented at the national level and are reviewed periodically						
	ltem		, by % of exp	erts	Commente	Decision after
			Neutral	Agreement	Comments	Round 1
Subdomain 5: Clinical interpretation		0%	0%	100%	-	Validated
Indicator 1: Guidelines for clinical interpretation of genomic results are defined		0%	0%	100% -		Validated
	ltem	Rating by % of experts Not adequate Adequate			Comments	Decision after Round 1
MLs	<ol> <li>No</li> <li>Guidelines for clinical interpretation of genomic results are defined locally (e.g. hospital, laboratory)</li> <li>Guidelines for clinical interpretation of genomic results are defined regionally/nationally (e.g. by national genetics societies)</li> <li>Guidelines for clinical interpretation of genomic results from internationally recognised bodies (e.g.</li> </ol>	ines for clinical ation of results are pocally (e.g. laboratory) ines for clinical ation of results are //nationally national societies) ines for clinical ation of results from onally		• I agree generally but if you give examples of internationally recognised bodies you should not give only one example from USA (ACGM) but Validated several bodies from different regions in the world, including European ones	Validated	





	ACMG, ClinGen) are implemented nationally 5. Guidelines for clinical interpretation of genomic results from internationally recognised bodies are implemented nationally, and there interactions with these international bodies for guideline definition for specific diseases (e.g. ACMG, ClinGen)					
	ltem	Rating	g by % of expe	erts	Comments	Decision after
item		Disagreement	Neutral	Agreement	comments	Round 1
Subdomai	Subdomain 6: Clinical reporting		0%	100%	-	Validated
	Indicator 1: Guidelines for clinical reporting of genomic results are defined		0%	93%	•for this reporting phase it would be important to mention that establishing a link with relevant patient associations is Validated; may be in levels of maturity?	Validated
	lá a m	Rating	g by % of expe	erts	Commente	Decision after
	ltem	Not adequate	e Ao	dequate	Comments	Round 1
1. No2. Consistent clinical reporting guidelines are developed at an organisation levelMLsMLsand practices for clinical reporting are defined and monitored, but not consistently enforced 4. National best practices for clinical		7%		93%	•What is meant by the term enforced in this context. Suggest remove enforced in these and then fine.	Validated





reporting are enforced		
and monitored		
5. Guidelines for clinical		
reporting are enforced		
at the national levels, in		
alignment with		
international standards		
and regularly reviewed		
based on changes in		
technological,		
regulatory and ethical		
considerations		





				Round 2				
ltem	Rating by %	6 of experts	Comments	Decision after	Rewordin	Agr	Comments	Decision after
	Not Relevant	Relevant		Round 1	g proposal	ee %	comments	Round 2
Domain VIII: Data management, standards and infrastructure	7%	93%	• The elements of the Domain VIII are obviously important to understand the maturity, however, I believe that this domain should be broader then data management standards and infrastructure, there are aspects of ehealth/digital health maturity more broad that as equally relevant. De way EHRs for example are organised, or how MS have, or not, the capacity to aggregate about an individual from different organisations, is, to me equally critical to the capacity to compare genomics data with outcomes, clinical profile, behaviours and	Validated	-	-	-	N/A

Table 8: Descriptive results for Domain VIII and respective sub-sections



Beyond One Million Genomes



					risk. So maybe a broader term - ehealth maturity at national and local level, or "data management" and "clinical information systems usage" standards and infra could be a better concept					
	ltem	Rating b	y% of e		Comments	Decision after	Rewordin	Agr ee	Comments	Decision after
	hem	Disagree ment	Neutr al	Agree ment	Comments	Round 1	g proposal	%		Round 2
securi		7%	0%	93%	•There is a potential overlap with Domain III, first subdomain. This should focus on technical safety of the infrastructure rather that data protection policy.	Validated	-	-	-	N/A
	ructure and es for data ty are	0%	0%	100%	-	Validated	-	-	-	N/A
14		Rating b	y% of e	xperts	Common to	Decision	Rewordin	Agr	Commente	Decision
ltem		Not adequate		lequate	Comments	after Round 1	g proposal	ee %	Comments	after Round 2
MLs	1. No 2. Security policies and infrastructure are defined at the organisation	14%		86%	•Data security is a big risk to public and patient trust so vital it is universal	Validated	-	-	-	N/A





level 3. Security policies and infrastructure are nationally defined but not sufficiently enforced 4. Security policies and infrastructure are established under national regulation and fully enforced 5. Security policies follow international best practices for data security and are regularly reviewed based on changes in technological, regulatory and ethical				•What does the term enforced mean in this context? Do you mean implemented?					
considerations	Rating by % of experts		Comments	Decision after	Rewordin	Agr ee	Comments	Decision after	
i cent	Disagree ment	Neutr al	Agree ment	connents	Round 1	g proposal	%	Comments	Round 2
Subdomain 2: Data discoverability (findable)	0%	7%	93%	-	Validated	-	-	-	N/A
Indicator 1: Guidelines for structuring metadata for datasets are established	14%	7%	<b>79</b> %	•There is a potential overlap with Domain VII, subdomain on metadata. This could focus whether there is a technical means	Reevaluate	-	86%	-The indicator should not only consider local level, but the aim should be national level	Validated



Beyond One Million Genomes



				of indeed finding the data, eg. a query mechanism exists. • the fact of using stable and unique identifiers should be Validated and specify which kind of such identifier is used; may be in level of maturity?				(as indicated by the maturity levels). -This should focus on infrastructur e, not on guidelines, suggestion: "Infrastructur e and practices for finding the relevant data are established." The guideline overlaps with Domain VII, subdomain 4. - Note: If accepted, the MLs need to be	
ltem		Rating by % of experts		Comments	Decision after	Rewordin	Agr ee	readjusted. Comments	Decision after
item.		Not adequate	Adequate		Round 1	g proposal	%	Commentes	Round 2
MLs	1. No 2. Guidelines for structuring metadata for datasets are established at the local level 3. Guidelines for structuring metadata for datasets established at the local level	7%	93%	•I think similar to some of the ISO and ACMG call outs, you should put (eg GA4GH and/or HL7 standards) explicitly here.	Validated	-	-	-	N/A





are documented and implemented, and their usage is tracked. 4. Guidelines for structuring metadata for datasets are established nationally 5. Guidelines for structuring metadata for datasets are established nationally, and there is national level interaction with the development and adoption of international standards for dataset metadata structure and labelling									
	Rating b	y % of ex	kperts		Decision	Rewordin	Agr		Decision
ltem	Disagree ment	Neutr al	Agree ment	Comments	after Round 1	g proposal	ee %	Comments	after Round 2
nain 3: Data management ible)	7%	0%	93%	-	Validated	-	-	-	N/A



Beyond One Million Genomes



sharin	tor 1: Data g policies and lows are ished	7%	7%	86%	-	Validated	(Swap position with next indicator)	-	-	N/A
ltem		Rating b	Ac	xperts lequate	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
MLs	1. No 2. Data access granting is fully manual, with individual agreements created with each request 3. Standardised local data sharing policies are established, with limited data flows managed electronically 4. Electronic systems are implemented to support data sharing policies and are adopted nationally 5. Application for data access is semi-automate d and follows international standards and	adequate		100%	-	Validated	- -	-	-	N/A



#### Beyond One Million Genomes



	there is national representation on the continued development of these standards									
		Rating b	y% of ex	operts		Decision	Rewordin	Agr	C	Decision
	ltem	Disagree ment	Neutr al	Agree ment	Comments	after Round 1	g proposal	ee %	Comments	after Round 2
		7%	14%	79%	• I agree but I would invert 1 and 2, putting first a governance framework and then a data sharing policy as data access governance framework is broader than just data sharing policy	Reevaluate	(Swap position with previous indicator)	100 %	-	Validated
ltem		Rating b Not adequate		kperts lequate	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
MLs	<ol> <li>No</li> <li>Data access governance is established locally (eg by department or institution)</li> <li>Scope of data access governance is defined nationally,</li> </ol>	14%		86%	•Maturity level 5 - Data access governance structure is institutionalised, protected from interference or organisational changes, and open to novel developments is confusing for me, what is meant? How can data	Validated with rewording	<ol> <li>No</li> <li>Data access</li> <li>governanc</li> <li>e is</li> <li>establishe</li> <li>d locally</li> <li>(eg by</li> <li>departme</li> <li>nt or</li> <li>institution</li> <li>)</li> <li>Scope</li> <li>of data</li> </ol>	-	-	N/A





with		access governance	access		
stakeholder		structures be	governanc		
consultation		open to novel	e is		
4. Data access		developments?	defined		
governance is		Surely in some	nationally		
led centrally,		cases good data	or		
fully		access governance	regionally,		
functional, and		structures are	with		
implementatio		there to prevent	stakeholde		
n is monitored		novel	r		
based on a		developments	consultati		
national work		from	on		
plan		inappropriately	4. Data		
5. Data access		accessing data?	access		
governance		, J	governanc		
structure is		<ul> <li>Should it be</li> </ul>	e is led		
institutionalise		national or	centrally,		
d, protected		regional? I often	fully		
from		feel the best unit	functional		
interference or		is the unit in	, and		
organisational		which healthcare	implement		
changes, and		is organised (this	ation is		
open to novel		is a bit of	monitored		
developments		meta-issue	based on a		
		applied to all uses	national		
		of the word	or regional		
		"national"). Think	work plan		
		Catalonia/Andaluc	5. Data		
		ia,	access		
		Scotland/England,	governanc		
		Baden-Wuttenberg	e		
		/Bavaria etc.	structure		
			is		
			institution		
			alised,		
			protected		
			from		
			interferen		
			ce or		
			organisati		
			onal		
			changes,		
			and open		
			to novel		
			to novel		





							developm ents			
	ltem	Rating by % of expertsDisagreeNeutrAgreementalment		Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2	
Recept interfa	main 4: tion and aces operable)	0%	14%	86%	-	Validated	-	-	-	N/A
for rec	tor 1: Guidelines cord level data ure are ished	7%	14%	<b>79</b> %	•Could indicator 1 and 2 be combined, or are they covered by Domain VII?	Reevaluate	-	93%	Still thinking that Indicator 1 (record level data structure) and 2 (dataset structure) could be combined.	Validated
ltem		Rating by Not adequate	-	xperts lequate	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
MLs	1. No 2. Guidelines for record structure for discovery are established at the local level 3. Guidelines for record structure for discovery are established at the local level and are documented, implemented and their usage is tracked	7%		93%	• What is meant by - Guidelines for record structure for discovery? Do you mean guidelines for the access of electronic health records for research purposes?	Validated	-	-	-	N/A





4. Guidelines for record structure for discovery are established nationally and are documented, implemented and their usage is tracked 5. Guidelines for record structure are established nationally and there are national level interactions for the development and adoption of international standards for dataset structure for discovery									
ltem	Rating b Disagree ment	Neutr al	Agree ment	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
Indicator 2: Guidelines for dataset structure are established	0%	21%	79%	-	Validated	-	-	-	N/A
	Rating by % of experts			Decision	Rewordin	Agr	C	Decision	
Item	Not adequate		lequate	Comments	after Round 1	g proposal	ee %	Comments	after Round 2
MLs	7%		93%	•See previous comment.	Validated	-	-	-	N/A





1. No				
2.Guidelines				
for dataset				
structure and				
access for				
discovery are				
established at				
the local level				
3. Guidelines				
for dataset				
structure and				
access for				
discovery are				
established at				
the local level				
and are				
documented,				
implemented				
and their				
usage is				
tracked				
4. Guidelines				
for record				
structure and				
access for				
discovery are				
established				
nationally and				
are				
documented,				
implemented				
and their				
usage is				
tracked				
5. Guidelines				
for dataset				
structure and				
access for				
discovery are				
established				
nationally and				
there are				
national level				
interactions				
for the	 			



#### Beyond One Million Genomes



	development and adoption of international standards									
	ltem	Rating b Disagree	y % of ex Neutr al	Agree	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
sharing is esta	tor 3: Data g infrastructure blished using a ted model	ment 0%	21%	79%	-	Validated	-	-	-	N/A
ltem		Rating b Not adequate	Ac	xperts lequate	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
MLs	<ol> <li>No</li> <li>Data sharing infrastructure is set up locally (eg by department or institution)3.</li> <li>Data sharing infrastructure interoperates within the region.</li> <li>Data sharing infrastructure interoperates with infrastructures from other regions.</li> <li>Data sharing infrastructure interoperates with an international federation</li> </ol>	14%		86%	<ul> <li>This indicator assumes that a federated model is better than another and this may not be always the case on a MS by MS level</li> <li>Data at national scale is needed so either they need to be interoperable</li> </ul>	Validated	-	-	-	N/A





	Rating t	oy % of e	xperts		Decision after	Rewordin	Agr	Comments	Decision
ltem	Disagree ment	Neutr al	Agree ment	Comments	after Round 1	g proposal	ee %	Comments	after Round 2
Indicator 4: Services for data reception to support interoperability are established	0%	21%	79%	-	Validated	-	-	-	N/A
ltem	Rating b Not adequate	by % of e	xperts dequate	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
<ul> <li>Alternational Standards</li> </ul>	7%		93%	•Similar to other standards, one can call out "(eg, GA4GH or HL7 standards)	Validated	-	-	-	N/A





accept data only in formats agreed nationally/regi onally and there is automatic quality control upon reception 5. All data received into genomic data services are automatically validated to ensure alignment with international standards									
ltem	Rating b Disagree ment	y % of e> Neutr al	kperts Agree ment	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2
Subdomain 5: Processing and analysis (reusable)	0%	7%	93%	-	Validated	-	-	-	N/A
Indicator 1: A computational and data infrastructure for medical reuse and secondary data analysis is available	7%	7%	86%	• I agree with this indicator but the reusability for research could be mentioned as a second indicator and link with the previous section where research use was addressed, to assure coherence	Validated	-	-	-	N/A
ltem	Rating b Not adequate	Ad	cperts lequate	Comments	Decision after Round 1	Rewordin g proposal	Agr ee %	Comments	Decision after Round 2





	1. No								
	1. NO 2. A								
	computational								
	and data								
	infrastructure								
	is available to								
	support local								
	analysis of								
	data								
	3. A								
	computational								
	and data								
	infrastructure								
	is available to								
	support trans-regional								
	analysis of								
	data								
	4. A								
MLs	computational	0%	100%	-	Validated	-	-	-	N/A
	and data								
	infrastructure								
	is in place to								
	support								
	national								
	analysis of								
	data 5. A								
	5. A computational								
	and data								
	infrastructure								
	supports								
	national								
	analysis of								
	data and is								
	aligned with								
	and supports								
	cross-border								
	data analysis								

N/A: Not Applicable.





Table 9: Delphi Panel Round 1 General Comments (exact transcription).

Items	Comments
Are there any other DOMAINS that have not been Validated in this MLM and you find are of great relevance for this model?	<ul> <li>I have already mentioned this in my previous comment. I believe broader ehealth maturity, particularly in what it respects to clinical information systems usage at both national (capacity to aggregate and summarise data on one individual across multiple organisations) and local levels.</li> <li>No I don't think so</li> <li>"I would add the word ""ethics"" in the title of the domain ""Legislation and policy". I would add a sub- domain on ""interactive tools with the public"" in the domain ""awareness and acceptance""</li> <li>Personally I think the Research level is too buried here - it is an important part, and has components like feedback</li> </ul>
Do you have any other comments?	<ul> <li>In the interest of the usability of the MLM tool, we should rather shorten the list of questions than expand it. See my suggestions for the relevant domains for reducing the number of questions.</li> <li>I would prefer to see legislation separated from policy. I believe in the data/genomics context, legal is very heavy load (complex, controversial etc etc) but policy, particularly enabling policy and policy on citizen participation, communicating the vision/goals of personalised medicine etc is and can be a very important activity, not to be "only associated" with law making</li> <li>This seems comprehensive</li> <li>It is not obvious from the titles of domains that the relation between research and clinical exercise of genomics are addressed. That would be important to be made visible from the start</li> </ul>
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN I and you find are of great relevance for this model? Please, specify.	<ul> <li>A successful initiative must involve all relevant actors such as universities and research environments. Further, in relation to "public awareness and acceptance" it might be relevant to not only communicate to the public through campaigns and literacy programs, but also communicate with the public through citizen advisory boards or the sort.</li> <li>I believe a "network" and a Participatory Activity for citizens "around" the national/regional entity is a sign of maturity. It is not uncommon to find very centralised bodies closed from society, this is not a good thing for the topic of genomic related research. models and ways to organise large parts of the society are still to be developed and matured and good practices should be shared in the EU.</li> </ul>





	• The fact of considering the centralised governance body and not a coordination of local/regional/institutional bodies may be a handicap; think of considering a coordination function as a possible governance mechanism.
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN II and you find are of great relevance for this model? Please, specify.	<ul> <li>bodies may be a nationapy, think of considering a coordination function as a possible governance mechanism.</li> <li>investments are often public-private partnerships, not solely public.</li> <li>Plan to ensure that most relevant technological solutions are used (sequencing platforms, methods) and that services are optimally centralised vs offered regionally</li> <li>I believe that public funding may not be the only way forward, and hence associating public funding to maturity may be incorrect. In some countries mix funding models may actually be a sign of higher maturity</li> <li>Consider evaluating the role/place of, or synergy with, private companies/structures in operating infrastructures for regional/national plans? Model could be synergy with industry in domain VI</li> <li>There is nothing about "access" as it relates to remote or regional communities. And who is able to order genomic testing (eg geneticist vs paediatrician for child with intellectual disability)</li> <li>criteria of inclusion should be indicated; maybe this can be in the clinical domain, but needs to be mentioned in the economic model</li> <li>I think a sub domain - Societal (patient/citizen) benefits - is still required but not narrowly linked to c/e model - perhaps - Societal benefits are quantified, considered and integrated in health system investment decision making regarding genomic medicine?</li> <li>I think there should be funding for the bridge between Research and Healthcare as at least a "nice to have".</li> </ul>
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN III and you find are of great relevance for this model? Please, specify.	<ul> <li>Eleven subdomains is too many: I suggest reducing to 7 by combining overlapping domains and adapting the indicator. Even seven subdomains is more than in any other domain.</li> <li>I believe in many aspects genomics data should NOT be treated differently from other health data. More regulation is not necessarily a sign of maturity. More practices, and preferably data sharing confidence building legal/regulatory frameworks that assume all ""restrictive aspects "" have been dealt with adequately but not necessarily ""in a special way"" with special laws."</li> <li>Consider evaluating the legislation and policies regarding data sharing at the supranational level?</li> <li>the international dimension I already mentioned should appear as it is important for patients ; it should be specified if it is feasible or not and the norms for it</li> </ul>
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN IV and you find are of great relevance for this model? Please, specify.	<ul> <li>Again: it might be relevant to not only communicate to the public through campaigns and literacy programs, but also communicate with the public through citizen advisory boards or the sort.</li> <li>I believe the campaigns should not be specific to genomic medicine. but personalised medicine and particularly biomedical research that Validates genomic/genetic aspects. But always framed in a bigger picture</li> <li>In this domain - there is no breakdown as to whether the communication strategies are adequate and high quality - vs whether or not they exist</li> </ul>





	<ul> <li>I consider that specific campaigns and communication towards the young public (schools, adolescents) should be specified and Validated as such</li> <li>See previous comments- I suggest changes needed</li> </ul>	
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN V and you find are of great relevance for this model? Please, specify.	<ul> <li>Other relevant educational programs: bioinformatics, molecular biologists, bioanalytics, lab technicians.</li> <li>Continuous education of medical doctors (even more importantly than other medical professionals), even though the young doctors would get the necessary education in med school, there are still large group of doctors making the decisions who potentially don't have adequate knowledge on genome medicine</li> <li>Consider education programs dedicated to patients and families?</li> <li>Need to also target existing clinicians - rather than just undergraduate programs</li> <li>In addition to MD, nurses and pharmacists I would add a line with "other health care professionals" as it is important that also physiotherapeutes and "sage-femmes" and others like dentists, orthoptists and orthophonists have at least some notions, given the broad scope of genetic diseases</li> <li>Not clear why the education subdomain is restricted to medicine, nursing and pharmacy? Should there be an additional indicator - Genomics is integrated in general curricula for all healthcare professionals? What about public health professionals?</li> </ul>	
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN VI and you find are of great relevance for this model? Please, specify.	<ul> <li>database architecture/storage.</li> <li>Note that I would Validate in this section the subdomain "Sequencing/ genotyping infrastructure" as a part of the clinical infrastructure.</li> <li>May be indicators mentioning the international aspect, as strategy with industry sector may be local or Validated international partnerships</li> <li>See comments</li> </ul>	
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN VII and you find are of great relevance for this model? Please, specify.	<ul> <li>database architecture/storage</li> <li>Note. The title of the domain can then simply read: "Clinical genomics guidelines"</li> <li>When analysis of raw data is performed in a centralised manner, is this data shared with local investigators for double check?</li> <li>The pipelines should be standardised throughout and ISO accredited</li> </ul>	
Are there any other SUBDOMAINS and/or INDICATORS that have not been Validated in DOMAIN VIII and you find are of great relevance for this model? Please, specify.	<ul> <li>The main issue in this domain is the potential overlap with previous domains. This could probably be addressed by reformulating some of the questions and indicators. Subdomain 4 (reception) might be better with only 2 indicators.</li> <li>I think subdomain 4 should be worked in broader level then genomics context, it should be included in a national interoperability strategy level</li> <li>the return of results aspect is not mentioned anywhere and is an important issue; it should be mentioned explicitly somewhere</li> </ul>	
Final Comments		





Now that you have gained a detailed view of the MLM framework, are there any other comments on the proposed Domains or other aspects of the MLM that you would like to make?	<ul> <li>I have made some restructuring proposals along the way.</li> <li>I think the Model as a whole covers well the national/org level, It could perhaps benefit from a domain on cross-border tools and cooperation mechanisms. also in light of future usage of the EHDS to foster research</li> <li>It is not a domain, but the difference between international standards and global standards used sometimes is not clear and would require either harmonisation for one of those terms only or precise definition of both underlying differences</li> <li>I think it is important to define what is in scope when using the term genomic medicine- the use of genomics in the practice of medicine or specifically specialists in clinical genetics/genomics. Also in addition to ISO standards the use of EQA schemes should be mentioned.</li> <li>I think one major meta thing is how to handle the national vs regional aspect. I think the key organising principle is that this maturity model should be appropriate to however a healthcare system is organised. In federal countries where healthcare is federated - Germany (Länder), Spain (autonomous regions), Italy (health care regions), UK (Scotland vs England, complications on Wales) etc the maturity model is to the highest level with full autonomy on healthcare. Otherwise looks good and although much of this is ""obvious"" nevertheless one needs to have a checklist and a scheme to show regions/countries on."</li> </ul>
If you have proposed a new Domain, please use this box to add your ideas regarding the respective Subdomains and Indicators.	"Cross-border domain: - legislation for cross border data sharing in genomics; - technical infrastructure to link up to the EHDS infra; - Education for Migrant sub-populations"

#### Table 10: Delphi Panel Round 2 General Comments

Generally you could consider having a level stating "under development" or "under discussion"





The current method of looking at the subdomains and their indicators one by one misses an important point of structure of the MFM. 1/ The Domains, Subdomains and Indicators in different parts of the MLM framework are not in balance. In most parts of the framework Indicator = Subdomain, ie. there is only one indicator per subdomain. In Section VIII, there are several well used indicators per subdomain, thus keeping the number of subdomains in check.

2/ Some subdomains would not deserve to be subdomains. This is very clear in the economic analysis which has 3 subdomains, while the hugely important issues of access to genomic medicine or its financing both have only one subdomain. Similarly, there are 11 subdomains in section III. Several could be combined, but keeping the indicators.

3/ Finally, a detail, but highlighting the problem of the current method is Subdomain 1 of Domain VII. The Subdomain as such is fine but would belong to Domain VI but the only way to indicate this is to protest the Subdomain itself.

There should be a meeting or a method to look at the whole once we have validated all wordings.

No. Overall good improvement after reformulations.

I think the Model as a whole covers well the national/org level, It could perhaps benefit from a domain on cross-border tools and cooperation mechanisms. This is particularly relevant as the future usage of the EHDS to foster research is envisioned.

I think one major meta thing is how to handle the national vs regional aspect. I think the key organising principle is that this maturity model should be appropriate to however a healthcare system is organised. In federal countries where healthcare is federated - Germany (Länder), Spain (autonomous regions), Italy (health care regions), UK (Scotland vs England, complications on Wales) etc the maturity model is to the highest level with full autonomy on healthcare.

Otherwise looks good and although much of this is "obvious" nevertheless one needs to have a checklist and a scheme to show regions/countries on.

It is not a domain, but the difference between international standards and global standards used sometimes is not clear and would require either harmonisation for one of those terms only or precise definition of both underlying differences

Generally you could consider having a level stating "under development" or "under discussion"





# Glossary

# Acceptance

Perceived usefulness of genomic medicine to patients. Recognition from citizens, patients and patients' associations of a positive impact of the use of genomic medicine on patients levels of satisfaction

# API

Application Programming Interface. A software intermediary that allows two applications to talk to each other.

#### Awareness

Public's level of understanding about the importance and implications of genomic medicine.

# Centrally

Based within a national or regional node.

# Clinical interpretation of genomic results

Translation of the technical output of a clinical genetic or genomic test into potentially clinically actionable information.

# Cost-effectiveness assessment

Cost-effectiveness analysis is a form of economic analysis that compares the relative costs and outcomes of different courses of action.

# Costed implementation plan

A multi-year roadmap that enables governments to prioritise interventions, engage stakeholders around one strategy, forecast costs and mobilise resources to meet identified gaps, namely to implement genomics in healthcare systems.





#### **Data protection**

Certainty that personal data is used fairly, lawfully and transparently - for specified, explicit purposes - in a way that is adequate, relevant and limited to only what is necessary, accurate and, where necessary, kept up-to-date, for no longer than is necessary, and handled in a way that ensures appropriate security, including protection against unlawful or unauthorised processing, access, loss, destruction or damage.

#### Data reuse

Reuse, or secondary use, of health data for purposes other than the primary reason for which they were originally saved. Other purposes may include scientific research, development and innovation activities, teaching and statistics.

#### **Data reception**

Uniform processes (such as quality control and standardisation) to receive (download) or access (through API) both data and metadata in a consistent way, enabling infrastructures to adhere to global standards and principles for genotypic and phenotypic data. It includes logically describing datasets to an extent that they can become actionable on the infrastructure, even if they are stored nationally or locally. (Adapted from the 1+MG Scoping paper)

#### Dataset structure

The dataset is formatted in a standard way to support interoperability, i.e. via use of international standards.

#### **Dedicated governance**

The process by which decisions are made and implemented. Governance is the process by which public institutions conduct public affairs and manage public resources.

#### Economic model

A structured approach to help decision-makers choose between alternative ways of using resources, by weighting the cost of an action against the benefits that it provides. It is frequently used to anticipate the costs and benefits of new health care technologies, policies and regulations.

**B1MG** 

#### Federated model



**Beyond One Million Genomes** 



125

A distributed network of repositories for sharing genomic information.

### **Further processing**

The processing of personal data for a different purpose(s) than the initially collected.

### Genetic data

Personal data related to the inherited or acquired genetic characteristics of an individual, which give unique information about his/her physiology or health, that result from an analysis of a biological sample from the individual in question. [ref. Art. 4(13) GDPR]

#### Guidelines for clinical interpretation of genomic results

Guidelines for translating the technical output of a genetic or genomic test into potentially clinically actionable information.

#### Guidelines for clinical reporting of genomic results

Guidelines for reporting the actionable results of a genetic or genomic test to the attending clinician and/or patient.

#### Health data

Personal data related to the physical or mental health of an individual independent of its origin (e.g. healthcare context, research, clinical trials, the data subject directly, smart devices). [ref. Art. 4 GDPR]

#### **HTA framework**

Health Technology Assessment framework. A multidisciplinary process that uses explicit methods to determine the value of health technology at different points in its lifecycle to help decision-makers make informed decisions.

#### ICT (clinical) tools

Information and communication technology, such as electronic health records, telehealth or online resources.

#### ISO

The International Organisation for Standardisation

#### Locally



Beyond One Million Genomes



Within a single institution, i.e. not beyond a lab, department or hospital.

#### Metadata

Data that provides information about other data. For example, the origin of the data, the processing details or the sharing permissions.

#### **Multidisciplinary teams**

Teams comprised of individuals who span across different areas of expertise to cover all knowledge areas required for genomic medicine.

#### No-cost access plan

Detailed set of rules that determines rights, duties and procedures to benefit from access to genomic tests at no cost

#### Norms

A set of principles of right action binding upon group members and serving to guide, control or regulate appropriate and acceptable behaviour. E.g. legislation, policies, professional regulations, codes of conduct.

#### Personal data

Data related to a living individual, who is likely to be identified by the data directly or combined with other data (e.g. through a pseudonym). [ref. Art. 4 GDPR]

# Primary bioinformatics analysis

The initial analysis that turns the machine output of genomic sequencing into genomic information for clinical/research interpretation or other contexts.

# **Reception and interfaces**

This consists of two areas.

(1) Reception. Uniform processes (such as quality control and standardisation) to receive (download) or access (through API) both data and metadata in a consistent way, enabling infrastructures to adhere to global standards and principles for genotypic and phenotypic data. It includes logically describing datasets to the extent that they can become actionable on the infrastructure, even if they are stored nationally or locally.





(2) Interfaces. Organisations offer interfaces (APIs) following international standards that form the technically interoperable infrastructure backbone.

[Adapted from the 1+MG Scoping paper]

#### Record

A dataset record is a collection of fields of information about the same person, item or object in a database. It can be thought of as a row of information within a database table.

# Secondary data analysis

The use of existing data, collected for a prior study, to pursue a research interest that is different to that of the original work. [ref: https://sru.soc.surrey.ac.uk/SRU22.html]

#### Sequence-associated metadata

Data that provides information about other data, specifically about genomic-sequence data.

### Societal benefits

Any advantages, gains or improvements as a result of employing a genomic approach to a group of people (e.g. patients, citizens).

#### Structured dataset metadata

Metadata (data that provides information about other data) for datasets that supports data discoverability using international standards.

#### **Vulnerable groups**

Vulnerable groups of population include children, adults with diminished capacities, the elderly, racial or ethnic minorities, the socioeconomically disadvantaged, underinsured or those with certain medical conditions who are at risk for unequal healthcare access, outcomes and exploitation.



